PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ji, Z; Wang, J; Yang, S; Tao, SJ; Shen, CQ; Wei, HX; Li, Q; Jin, PS				Ji, Zhe; Wang, Jian; Yang, Shuai; Tao, Shengjun; Shen, Caiqi; Wei, Hanxiao; Li, Qiang; Jin, Peisheng			Graphene oxide accelerates diabetic wound repair by inhibiting apoptosis of Ad-MSCs via Linc00324/miR-7977/STK4 pathway	FASEB JOURNAL			English	Article						adipose-derived mesenchymal stem cells; diabetic wound; graphene oxide; Linc00324; miR-7977	CELL; PROLIFERATION; MIGRATION	Many studies have shown that graphene oxide (GO) promotes proliferation and differentiation of a variety of stem cells. However, its effect on adipose-derived mesenchymal stem cell (Ad-MSCs) apoptosis is still unclear. Apoptosis is a significant factor affecting stem cell-based treatment of diabetic wounds. Therefore, we explored the effect of GO on Ad-MSC apoptosis and diabetic wound healing. In this study, qRT-PCR was used to detect Ad-MSC expression of LncRNAs, miRNAs, and mRNAs under high-glucose environment. RNA immunoprecipitation (RIP), RNA pull-down, and luciferase assays were used to detect interactions of specific lncRNAs, miRNAs, and mRNAs. The effects of GO on Ad-MSC apoptosis were explored by flow cytometry, TUNEL assay, and Western blot. A diabetic wound model was used to explore the function of Linc00324 on Ad-MSC reparative properties in vivo. As a result, GO inhibited high glucose-induced apoptosis in Ad-MSCs, and Linc00324 contributed to the anti-apoptotic effect of GO. RIP and RNA pull-down confirmed that Linc00324 directly interacted with miR-7977, functioning as a miRNA sponge to regulate expression of the miR-7977 target gene STK4 (MST1) and downstream signaling pathways. In addition, GO reduced the apoptosis of Ad-MSCs in wounds and promoted wound healing. Taken together, these findings suggest GO may be a superior auxiliary material for Ad-MSCs to facilitate diabetic wound healing via the Linc00324/miR-7977/STK4 pathway.	[Ji, Zhe; Wang, Jian; Yang, Shuai; Tao, Shengjun; Shen, Caiqi; Wei, Hanxiao; Li, Qiang; Jin, Peisheng] Xuzhou Med Univ, Dept Plast Surg, Affiliated Hosp, Huaihai West Rd, Xuzhou, Jiangsu, Peoples R China; [Jin, Peisheng] Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc, Xuzhou, Jiangsu, Peoples R China; [Jin, Peisheng] Xuzhou Med Univ, Jiangsu Canc Biotherapy Inst, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Li, Q; Jin, PS (corresponding author), Xuzhou Med Univ, Dept Plast Surg, Affiliated Hosp, Huaihai West Rd, Xuzhou, Jiangsu, Peoples R China.	fallin1983@163.com; 100000401006@xzhmu.edu.cn	Zhe, Ji/GLR-4104-2022		National Natural Science Foundation of China [82072819]; National Natural Science Foundation of Jiangsu Province [BK20201155]; China Postdoctoral Science Foundation [2019T120462]; Jiangsu Postdoctoral Science Foundation [2019K155]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX20_2456, KYCX20_2480]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jiangsu Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Postgraduate Research & Practice Innovation Program of Jiangsu Province	This study was supported by grants from the National Natural Science Foundation of China (82072819), the National Natural Science Foundation of Jiangsu Province (BK20201155), China Postdoctoral Science Foundation (2019T120462), Jiangsu Postdoctoral Science Foundation (2019K155), and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX20_2456, KYCX20_2480).	Ali T, 2020, ELIFE, V9, DOI 10.7554/eLife.60583; Barman PK, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00528; Chen LY, 2020, J CELL BIOCHEM, V121, P3382, DOI 10.1002/jcb.29612; Cheng YH, 2022, COLLOID SURFACE B, V209, DOI 10.1016/j.colsurfb.2021.112150; Choe G, 2019, NANOSCALE, V11, P23275, DOI 10.1039/c9nr07643c; Conlon TM, 2020, NATURE, V588, P151, DOI 10.1038/s41586-020-2882-8; Dekoninck S, 2019, NAT CELL BIOL, V21, P18, DOI 10.1038/s41556-018-0237-6; Dhoke NR, 2020, MOL THER, V28, P1314, DOI 10.1016/j.ymthe.2020.02.014; Dong XJ, 2020, PROSTAG LEUKOTR ESS, V161, DOI 10.1016/j.plefa.2020.102179; Fu C, 2019, ARTIF CELL NANOMED B, V47, P1867, DOI 10.1080/21691401.2019.1613422; Garcia-Alegria E, 2016, SCI REP-UK, V6, DOI 10.1038/srep25917; Guo F, 2020, CELL CYCLE, V19, P1997, DOI 10.1080/15384101.2020.1783481; Hehenberger Karin, 1998, Wound Repair and Regeneration, V6, P135, DOI 10.1046/j.1524-475X.1998.60207.x; Horiguchi H, 2016, HAEMATOLOGICA, V101, P437, DOI 10.3324/haematol.2015.134932; Huang RY, 2019, BIOMATER SCI-UK, V7, P4248, DOI 10.1039/c9bm00939f; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kim JH, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00259; Kim J, 2013, J BIOMED MATER RES A, V101, P3520, DOI 10.1002/jbm.a.34659; Kim TH, 2013, BIOMATERIALS, V34, P8660, DOI 10.1016/j.biomaterials.2013.07.101; Kovanecz I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164044; Lasocka I, 2019, INT J NANOMED, V14, P2281, DOI 10.2147/IJN.S190928; Li B, 2020, J MOL ENDOCRINOL, V65, P69, DOI 10.1530/JME-19-0242; Li Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0615-9; Lou D, 2020, BIOACT MATER, V5, P667, DOI 10.1016/j.bioactmat.2020.04.018; Moradi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58099-z; Ni X, 2019, EUR REV MED PHARMACO, V23, P10740, DOI 10.26355/eurrev_201912_19775; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Nyambat B, 2018, J MATER CHEM B, V6, P979, DOI 10.1039/c7tb02480k; Peng XZ, 2020, J CELL MOL MED, V24, P304, DOI 10.1111/jcmm.14728; Ren CX, 2018, ADV SCI, V5, DOI 10.1002/advs.201700595; Sekula-Stryjewska M, 2021, MAT SCI ENG C-MATER, V119, DOI 10.1016/j.msec.2020.111614; Turunen SP, 2019, CELL DEATH DIFFER, V26, P2577, DOI 10.1038/s41418-019-0321-x; Tyc KM, 2021, LAB INVEST, V101, P503, DOI 10.1038/s41374-020-00498-x; Tyeb S, 2020, BIOMACROMOLECULES, V21, P294, DOI 10.1021/acs.biomac.9b01355; Wear-Maggitti K, 2004, ANN PLAS SURG, V52, P519, DOI 10.1097/01.sap.0000122857.49274.8c; Wu SK, 2020, J CELL PHYSIOL, V235, P339, DOI 10.1002/jcp.28973; Xie MY, 2018, J CELL MOL MED, V22, P3595, DOI 10.1111/jcmm.13639; Xu SJ, 2011, ANAL CHEM, V83, P3817, DOI 10.1021/ac200237j; Yan HL, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0047-y; Yoshida M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213220; Yu XY, 2019, IUBMB LIFE, V71, P1611, DOI 10.1002/iub.2102; Zambrano-Andazol I, 2020, MAT SCI ENG C-MATER, V114, DOI 10.1016/j.msec.2020.111075; Zhang YX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.432; Zhu JY, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07302-5	44	0	0	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22623	10.1096/fj.202201079RR	http://dx.doi.org/10.1096/fj.202201079RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5M0HV	36269304				2022-12-26	WOS:000870788800001
J	Liao, YJ; Peng, XJ; Li, XZ; Wu, DK; Qiu, SF; Tang, XM; Zhang, DS				Liao, Yingjun; Peng, Xiongjun; Li, Xiaozhou; Wu, Dengke; Qiu, Shuangfa; Tang, Xianming; Zhang, Dongshan			CircRNA_45478 promotes ischemic AKI by targeting the miR-190a-5p/PHLPP1 axis	FASEB JOURNAL			English	Article						AKI; apoptosis; circular RNA; miR-190a-5p; PHLPP1	RENAL FIBROSIS; SEPTIC AKI; INHIBITION; ACTIVATION; APOPTOSIS; BIOMARKER; PATHWAY; UUO	A few studies suggested that circular RNAs were involved in the development of ischemic acute kidney injury (AKI). However, the function and regulation mechanism of circRNA_45478 in ischemic AKI remains unknown. In the present study, ischemic injury induced the expressions of circRNA_45478 in mouse proximal tubule-derived cell lines (BUMPT cells) and kidneys of C57BL/6 mice. Functionally, circRNA_45478 mediated I/R-induced apoptosis in BUMPT cells. Mechanistically, circRNA_45478 upregulated the expression of Pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase 1 (PHLPP1) via sponging of microRNA (miR)-190a-5p. Finally, inhibition of circRNA_45478 significantly alleviated the progression of ischemic AKI through regulation of the miR-190a-5p/PHLPP1 pathway. Taken together, our data showed that circRNA_45478/miR-190a-5p/PHLPP1 axis mediated the progression of ischemic AKI.	[Liao, Yingjun; Li, Xiaozhou; Wu, Dengke; Qiu, Shuangfa; Tang, Xianming; Zhang, Dongshan] Cent South Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha 410011, Hunan, Peoples R China; [Liao, Yingjun; Zhang, Dongshan] Cent South Univ, Xiangya Hosp 2, Dept Nephrol, Changsha, Peoples R China; [Peng, Xiongjun] Cent South Univ, Xiangya Hosp 2, Dept Med Equipment, Changsha, Peoples R China; [Li, Xiaozhou; Wu, Dengke; Qiu, Shuangfa; Tang, Xianming; Zhang, Dongshan] Cent South Univ, Xiangya Hosp 2, Emergency Med & Difficult Dis Inst, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University	Tang, XM; Zhang, DS (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha 410011, Hunan, Peoples R China.	txm750916@csu.edu.cn; dongshanzhang@csu.edit.cn			Changsha Science and Technology Bureau project [kq1907144, kq2014242, kq2001039]; Department of Science and Technology of Hunan Province project of International Cooperation and Exchanges [2020WK2009]; China Hunan Provincial Science and Technology Department (HSTD) [2021sk4004]; Key Project of Hunan Provincial Science and Technology Innovation [2020SK1014]; National Natural Science Foundation of China (NSFC) [81870475, 81570646, 81770951]; Natural Science Foundation of Hunan Province [2021JJ30959]	Changsha Science and Technology Bureau project; Department of Science and Technology of Hunan Province project of International Cooperation and Exchanges; China Hunan Provincial Science and Technology Department (HSTD); Key Project of Hunan Provincial Science and Technology Innovation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	Changsha Science and Technology Bureau project, Grant/Award Number: kq1907144, kq2014242 and kq2001039; Department of Science and Technology of Hunan Province project of International Cooperation and Exchanges, Grant/Award Number: 2020WK2009; China Hunan Provincial Science and Technology Department (HSTD), Grant/Award Number: 2021sk4004; Key Project of Hunan Provincial Science and Technology Innovation, Grant/Award Number: 2020SK1014; National Natural Science Foundation of China (NSFC), Grant/Award Number: 81870475, 81570646 and 81770951; Natural Science Foundation of Hunan Province, Grant/Award Number: 2021JJ30959	Abdalkader M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00466; Ai K, 2022, MOL THER-NUCL ACIDS, V28, P77, DOI 10.1016/j.omtn.2022.02.015; Altesha MA, 2019, J CELL PHYSIOL, V234, P5588, DOI 10.1002/jcp.27384; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Chen X, 2019, THERANOSTICS, V9, P588, DOI 10.7150/thno.29678; Cheng ZA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11162-4; Fu LY, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118707; Garikipati VNS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11777-7; Ge YN, 2019, MOL THER-NUCL ACIDS, V17, P741, DOI 10.1016/j.omtn.2019.07.007; Gomes BC, 2020, CAN J KIDNEY HEALTH, V7, DOI 10.1177/2054358120934215; Han SJ, 2019, KIDNEY RES CLIN PRAC, V38, P427, DOI 10.23876/j.krcp.19.062; Hosohata K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111448; Huang T, 2022, INT IMMUNOPHARMACOL, V106, DOI 10.1016/j.intimp.2022.108614; Kerins MJ, 2018, ANTIOXID REDOX SIGN, V29, P1756, DOI 10.1089/ars.2017.7176; Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7; Li PL, 2020, MOL THER-NUCL ACIDS, V20, P879, DOI 10.1016/j.omtn.2020.05.016; Li Q, 2015, TUMOR BIOL, V36, P2007, DOI 10.1007/s13277-014-2807-y; Li XZ, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103859; Li XZ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18304-z; Li YX, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/8709298; Liu J, 2022, APOPTOSIS, V27, P531, DOI 10.1007/s10495-022-01730-3; Liu XB, 2018, MOL THER-NUCL ACIDS, V10, P142, DOI 10.1016/j.omtn.2017.12.001; Mathur A, 2021, MOL CELL BIOCHEM, V476, P3681, DOI 10.1007/s11010-021-04177-3; Mathur A, 2018, FREE RADICAL BIO MED, V120, P414, DOI 10.1016/j.freeradbiomed.2018.04.550; Meng FH, 2022, RENAL FAILURE, V44, P672, DOI 10.1080/0886022X.2022.2032746; Peng JP, 2015, KIDNEY INT, V87, P137, DOI 10.1038/ki.2014.226; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Sun CC, 2017, MOL THER-NUCL ACIDS, V9, P100, DOI 10.1016/j.omtn.2017.08.015; Wang SH, 2020, CLIN BREAST CANCER, V20, P422, DOI 10.1016/j.clbc.2020.04.006; Xiao Y, 2022, FASEB J, V36, DOI 10.1096/fj.202200064RR; Xie YX, 2021, MOL THER-NUCL ACIDS, V23, P76, DOI 10.1016/j.omtn.2020.09.028; Xu X, 2019, FASEB J, V33, P4513, DOI 10.1096/fj.201801515R; Yang RH, 2017, SCI REP-UK, V7, DOI 10.1038/srep43409; Yi L, 2021, AGING-US, V13, P12780, DOI 10.18632/aging.202947; Zhang MJ, 2020, J CELL MOL MED, V24, P4612, DOI 10.1111/jcmm.15123; Zhang P, 2020, MOL THER-NUCL ACIDS, V19, P1027, DOI 10.1016/j.omtn.2019.12.037	36	0	0	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2022	36	12							e22633	10.1096/fj.202201070R	http://dx.doi.org/10.1096/fj.202201070R			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5U5DY	36315192				2022-12-26	WOS:000876568600001
J	Matsunaga, Y; Tamura, Y; Takahashi, K; Kitaoka, Y; Takahashi, Y; Hoshino, D; Kadoguchi, T; Hatta, H				Matsunaga, Yutaka; Tamura, Yuki; Takahashi, Kenya; Kitaoka, Yu; Takahashi, Yumiko; Hoshino, Daisuke; Kadoguchi, Tomoyasu; Hatta, Hideo			Branched-chain amino acid supplementation suppresses the detraining-induced reduction of mitochondrial content in mouse skeletal muscle	FASEB JOURNAL			English	Article						branched-chain amino acid; detraining; mitochondria; mitochondrial biogenesis; mitophagy; skeletal muscle	PROTEIN-SYNTHESIS; EXERCISE; ENDURANCE; ADAPTATIONS; LEUCINE; GLYCOGEN; INCREASES; AUTOPHAGY; PGC-1-ALPHA; BIOGENESIS	Exercise training enhances oxidative capacity whereas detraining reduces mitochondrial content in skeletal muscle. The strategy to suppress the detraining-induced reduction of mitochondrial content has not been fully elucidated. As previous studies reported that branched-chain amino acid (BCAA) ingestion increased mitochondrial content in skeletal muscle, we evaluated whether BCAA supplementation could suppress the detraining-induced reduction of mitochondrial content. Six-week-old male Institute of Cancer Research (ICR) mice were randomly divided into four groups as follows: control (Con), endurance training (Tr), detraining (DeTr), and detraining with BCAA supplementation (DeTr + BCAA). Mice in Tr, DeTr, and DeTr + BCAA performed treadmill running exercises [20-30 m/min, 60 min, 5 times/week, 4 weeks]. Then, mice in DeTr and DeTr + BCAA were administered with water or BCAA [0.6 mg/g of body weight, twice daily] for 2 weeks of detraining. In whole skeletal muscle, mitochondrial enzyme activities and protein content were decreased after 2 weeks of detraining, but the reduction was suppressed by BCAA supplementation. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) protein content, a master regulator of mitochondrial biogenesis, was decreased by detraining irrespective of BCAA ingestion. Regarding mitochondrial degradation, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), a mitophagy-related protein, was significantly higher in the Tr group than in the DeTr + BCAA group, but not different from in the DeTr group. With respect to mitochondrial quality, BCAA ingestion did not affect oxygen consumption rate (OCR) and reactive oxygen species (ROS) production in isolated mitochondria. Our findings suggest that BCAA ingestion suppresses the detraining-induced reduction of mitochondrial content partly through inhibiting mitophagy.	[Matsunaga, Yutaka; Tamura, Yuki; Takahashi, Kenya; Kitaoka, Yu; Takahashi, Yumiko; Hoshino, Daisuke; Kadoguchi, Tomoyasu; Hatta, Hideo] Univ Tokyo, Dept Sports Sci, Tokyo, Japan; [Tamura, Yuki] Nippon Sport Sci Univ, Grad Sch Hlth & Sport Sci, Tokyo, Japan; [Kitaoka, Yu] Kanagawa Univ, Dept Human Sci, Yokohama, Kanagawa, Japan; [Hoshino, Daisuke] Univ Electrocommun, Dept Engn Sci, Tokyo, Japan	University of Tokyo; Nippon Sport Science University; Kanagawa University; University of Electro-Communications - Japan	Matsunaga, Y (corresponding author), Univ Tokyo, Dept Sports Sci, Meguro Ku, 3-8-1 Komaba, Tokyo 1538902, Japan.	y_matsunaga@idaten.c.u-tokyo.ac.jp		Kadoguchi, Tomoyasu/0000-0001-6336-5160; Takahashi, Yumiko/0000-0002-4762-0982; Kitaoka, Yu/0000-0001-6932-2735	Kozuki Foundation; Japan Society for the Promotion of Science [19K24310]	Kozuki Foundation; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Kozuki Foundation research grant program; Japan Society for the Promotion of Science, Grant/Award Number: 19K24310	Anthony JC, 2000, J NUTR, V130, P2413; Bartolome A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00441-17; BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; Blocquiaux S, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110860; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chesley A, 1996, AM J PHYSIOL-ENDOC M, V270, pE328, DOI 10.1152/ajpendo.1996.270.2.E328; COYLE EF, 1985, J APPL PHYSIOL, V59, P853, DOI 10.1152/jappl.1985.59.3.853; COYLE EF, 1986, J APPL PHYSIOL, V60, P95, DOI 10.1152/jappl.1986.60.1.95; COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857; Crozier SJ, 2005, J NUTR, V135, P376, DOI 10.1093/jn/135.3.376; D'Antona G, 2010, CELL METAB, V12, P362, DOI 10.1016/j.cmet.2010.08.016; Dhingra R, 2013, CIRC-HEART FAIL, V6, P335, DOI 10.1161/CIRCHEARTFAILURE.112.000061; Drake JC, 2016, FASEB J, V30, P13, DOI 10.1096/fj.15-276337; FITTS RH, 1975, AM J PHYSIOL, V228, P1029, DOI 10.1152/ajplegacy.1975.228.4.1029; Gilkerson RW, 2012, HUM MOL GENET, V21, P978, DOI 10.1093/hmg/ddr529; Granata C, 2016, FASEB J, V30, P3413, DOI 10.1096/fj.201500100R; Guan YT, 2019, EXERC SPORT SCI REV, V47, P151, DOI 10.1249/JES.0000000000000192; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002; Iwanaka N, 2010, J APPL PHYSIOL, V108, P274, DOI 10.1152/japplphysiol.00420.2009; Jackman SR, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00390; Kadowaki Motoni, 2006, Molecular Aspects of Medicine, V27, P426, DOI 10.1016/j.mam.2006.08.010; Karlsson HKR, 2004, AM J PHYSIOL-ENDOC M, V287, pE1, DOI 10.1152/ajpendo.00430.2003; Kitaoka Y, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.13998; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Leadsham JE, 2013, CELL METAB, V18, P279, DOI 10.1016/j.cmet.2013.07.005; Li HL, 2012, AM J PHYSIOL-ENDOC M, V303, pE1234, DOI 10.1152/ajpendo.00198.2012; Lira VA, 2013, FASEB J, V27, P4184, DOI 10.1096/fj.13-228486; LO S, 1970, J APPL PHYSIOL, V28, P234, DOI 10.1152/jappl.1970.28.2.234; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MacLean D. A., 1994, American Journal of Physiology, V267, pE1010; Macleod KF, 2020, ANNU REV CANC BIOL, V4, P41, DOI 10.1146/annurev-cancerbio-030419-033405; MADSEN K, 1993, J APPL PHYSIOL, V75, P1444, DOI 10.1152/jappl.1993.75.4.1444; MARTIN WH, 1986, J AM COLL CARDIOL, V7, P982, DOI 10.1016/S0735-1097(86)80215-7; Melser S, 2015, BBA-MOL CELL RES, V1853, P2812, DOI 10.1016/j.bbamcr.2015.05.010; Moberg M, 2016, AM J PHYSIOL-CELL PH, V310, pC874, DOI 10.1152/ajpcell.00374.2015; Moyzis AG, 2015, AM J PHYSIOL-HEART C, V308, pH183, DOI 10.1152/ajpheart.00708.2014; Mujika I, 2000, SPORTS MED, V30, P79, DOI 10.2165/00007256-200030020-00002; Ni HM, 2015, REDOX BIOL, V4, P6, DOI 10.1016/j.redox.2014.11.006; Ogasawara R, 2013, J APPL PHYSIOL, V114, P934, DOI 10.1152/japplphysiol.01161.2012; Perry CGR, 2010, J PHYSIOL-LONDON, V588, P4795, DOI 10.1113/jphysiol.2010.199448; Putti R, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00426; Rivera ME, 2022, ENDOCRINE, V76, P18, DOI 10.1007/s12020-021-02939-z; Sanchez AMJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060542; Sanchez AMJ, 2018, BIOCHEM BIOPH RES CO, V499, P493, DOI 10.1016/j.bbrc.2018.03.176; Shimomura Y., 2012, J PHYS FITNESS SPORT, V1, P219, DOI [10.7600/jpfsm.1.219, DOI 10.7600/JPFSM.1.219]; Skein M, 2012, EUR J APPL PHYSIOL, V112, P2859, DOI 10.1007/s00421-011-2253-0; Stancliffe RA., 2012, THESIS U TENNESSEE K; Tadaishi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028290; Tamai Y, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2020.111181; Tamura Y, 2020, AM J PHYSIOL-CELL PH, V319, pC1029, DOI 10.1152/ajpcell.00494.2019; Tamura Y, 2015, J PHYSIOL-LONDON, V593, P2707, DOI 10.1113/JP270093; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104; Tomiya S, 2019, AM J PHYSIOL-REG I, V317, pR649, DOI 10.1152/ajpregu.00118.2019; Uguccioni G, 2011, AM J PHYSIOL-ENDOC M, V300, pE361, DOI 10.1152/ajpendo.00292.2010; Wakabayashi Y, 2020, AM J PHYSIOL-REG I, V318, pR677, DOI 10.1152/ajpregu.00089.2019; WIBOM R, 1992, J APPL PHYSIOL, V73, P2004, DOI 10.1152/jappl.1992.73.5.2004; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yamashita SI, 2021, J CELL PHYSIOL, V236, P7612, DOI 10.1002/jcp.30404; Zhang FY, 2016, EBIOMEDICINE, V13, P157, DOI 10.1016/j.ebiom.2016.10.013; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhong YZ, 2019, NUTRITION, V60, P217, DOI 10.1016/j.nut.2018.09.032	66	0	0	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2022	36	12							e22628	10.1096/fj.202200588R	http://dx.doi.org/10.1096/fj.202200588R			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5W1LP	36322028				2022-12-26	WOS:000877683500001
J	Kaufman, PD; Huang, S; Pederson, T				Kaufman, Paul D.; Huang, Sui; Pederson, Thoru			The nuclear bodies conference: Hubs of genomic activity, June 24-28, Western Shore, Nova Scotia, Canada	FASEB JOURNAL			English	Editorial Material						genome coordination; nucleus organization		This conference brought together leaders in the investigation of various bodies that populate the nucleus, a field that complements research on chromosome biology. These nuclear bodies had been receiving increasing attention as hubs of genome activity and the new findings reported at the conference strongly confirmed and significantly expanded this principle.	[Kaufman, Paul D.] Univ Massachusetts, Chan Med Sch, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA; [Huang, Sui] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; [Pederson, Thoru] Univ Massachusetts, Chan Sch Med, Dept Biochem & Mol Biotechnol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Northwestern University; Feinberg School of Medicine; University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Chan Sch Med, Dept Biochem & Mol Biotechnol, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu		Kaufman, Paul/0000-0003-3089-313X	National Institutes of Health [R13 CA271711-01]; Keith R. Porter Endowment for Cell Biology; Nikon; New England Biolabs; Ionis Pharmaceuticals; FASEB; Company of Biologists; ChromaTech	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keith R. Porter Endowment for Cell Biology; Nikon; New England Biolabs; Ionis Pharmaceuticals; FASEB; Company of Biologists; ChromaTech	National Institutes of Health, Grant/Award Number: R13 CA271711-01; Keith R. Porter Endowment for Cell Biology; Nikon; New England Biolabs; Ionis Pharmaceuticals; FASEB; Company of Biologists; ChromaTech		0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22588	10.1096/fj.202201455R	http://dx.doi.org/10.1096/fj.202201455R			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5R1XF	36287614				2022-12-26	WOS:000874310000001
J	Chen, H; Chen, XH; Zhang, ZJ; Bao, WH; Gao, ZQ; Li, DF; Xie, XY; Zhou, P; Yang, CX; Zhou, ZQ; Pan, JY; Kuang, XQ; Tang, RM; Feng, ZF; Zhou, LH; Zhu, DC; Yang, JA; Wang, L; Huang, HB; Tang, DL; Liu, JB; Jiang, LL				Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Zhou, Zhongqiu; Pan, Jinyuan; Kuang, Xiangqin; Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan; Zhu, Dachun; Yang, Jianan; Wang, Lan; Huang, Hongbiao; Tang, Daolin; Liu, Jinbao; Jiang, Lili			Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-kappa B via ANXA1-dependent ubiquitination of NEMO	ONCOGENE			English	Article							GLIOBLASTOMA; COMPLEX; CANCER; EXOSOMES; RIP1; IKK	Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-kappa B signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-kappa B essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-kappa B pathway, which may provide potential therapeutic target for clinical intervention in glioma.	[Chen, Han; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Yang, Jianan; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China; [Chen, Xuhong] Southern Univ Sci & Technol Hosp, Med Res Ctr, Shenzhen 518055, Peoples R China; [Zhou, Zhongqiu] Sichuan Univ, Alliance Hosp West China Univ Hosp 2, Meishan Women & Childrens Hosp, Meishan 620000, Peoples R China; [Pan, Jinyuan] Yangtze Univ, Dept Oncol, Huanggang Cent Hosp, Huanggang 438000, Peoples R China; [Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan] Guangzhou Med Univ, Qingyuan Peoples Hosp, Affiliated Hosp 6, Guangzhou 511518, Peoples R China; [Zhu, Dachun] Shenzhen Baoan Womens & Childirens Hosp, Dept Operating Room, Shenzhen 518000, Peoples R China; [Yang, Jianan] Guangzhou Med Univ, Dept Urol Oncosurg, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Wang, Lan] Guangdong Pharmaceut Univ, Sch Basic Courses, Dept Pathogen Biol & Immunol, Guangzhou 510006, Peoples R China; [Tang, Daolin] UT Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA	Guangzhou Medical University; Guangzhou Medical University; Southern University of Science & Technology; Sichuan University; Yangtze University; Guangzhou Medical University; Guangzhou Medical University; Guangdong Pharmaceutical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China.; Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China.	jliu@gzhmu.edu.cn; jianglili@gzhmu.edu.cn			Basic and Applied Research Projects of Guangzhou Science and Technology Bureau [202002030067]; Natural Science Foundation of China [82273464, 81972619, 81672874, 81972399]; Natural Science Foundation of Guangdong Province [2021A1515012477, 2022A1515012260]; Key Discipline of Guangzhou Education Bureau (Basic Medicine) [201851839]; Natural Science Foundation research team of Guangdong Province [2018B030312001]; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital [202011-202]; Innovative Academic Team of Guangzhou Education System [1201610014]; Guangzhou key medical discipline construction project fun	Basic and Applied Research Projects of Guangzhou Science and Technology Bureau; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Discipline of Guangzhou Education Bureau (Basic Medicine); Natural Science Foundation research team of Guangdong Province; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital; Innovative Academic Team of Guangzhou Education System; Guangzhou key medical discipline construction project fun	This work was supported by the Basic and Applied Research Projects of Guangzhou Science and Technology Bureau (202002030067), the Natural Science Foundation of China (82273464, 81972619, 81672874, and 81972399), the Natural Science Foundation of Guangdong Province (2021A1515012477 and 2022A1515012260), the Key Discipline of Guangzhou Education Bureau (Basic Medicine) (201851839), the Natural Science Foundation research team of Guangdong Province (2018B030312001), the open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital (202011-202), the Innovative Academic Team of Guangzhou Education System (1201610014), and the Guangzhou key medical discipline construction project fun.	Abels ER, 2019, TRENDS CANCER, V5, P393, DOI 10.1016/j.trecan.2019.05.006; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Aoshima M, 2019, J DERMATOL SCI, V95, P107, DOI 10.1016/j.jdermsci.2019.07.009; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cahill KE, 2016, NEURO-ONCOLOGY, V18, P329, DOI 10.1093/neuonc/nov265; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; de Vrij J, 2015, INT J CANCER, V137, P1630, DOI 10.1002/ijc.29521; Delgado-Lopez PD, 2016, CLIN TRANSL ONCOL, V18, P1062, DOI 10.1007/s12094-016-1497-x; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gao XF, 2020, CELL REP, V30, P2489, DOI 10.1016/j.celrep.2020.01.089; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Ji JX, 2021, CELL DEATH DIFFER, V28, P367, DOI 10.1038/s41418-020-00606-w; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lauko A, 2022, SEMIN CANCER BIOL, V82, P162, DOI 10.1016/j.semcancer.2021.02.014; Lee IY, 2019, MOL CELL, V73, P1138, DOI 10.1016/j.molcel.2019.01.022; Liu YF, 2020, AGING-US, V12, P21559, DOI 10.18632/aging.103945; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Matsui T, 2004, GENOMICS, V84, P384, DOI 10.1016/j.ygeno.2004.03.010; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Niu JX, 2011, EMBO J, V30, P3741, DOI 10.1038/emboj.2011.264; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Pribyl M, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010108; Pribyl M, 2020, MOL ONCOL, V14, P2403, DOI 10.1002/1878-0261.12768; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Sarkar S, 2009, J NEURO-ONCOL, V91, P157, DOI 10.1007/s11060-008-9695-1; Song K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI129374; Srivastava C, 2020, BMC CANCER, V20, DOI 10.1186/s12885-019-6435-1; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wang SS, 2017, MOL THER-NUCL ACIDS, V8, P482, DOI 10.1016/j.omtn.2017.07.015; Wei S, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13090; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Wu YB, 2018, AM J TRANSL RES, V10, P881; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Yanovich-Arad G, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108787; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	52	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5253	5265		10.1038/s41388-022-02520-6	http://dx.doi.org/10.1038/s41388-022-02520-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316443				2022-12-26	WOS:000876857500001
J	Song, YL; Yang, MH; Zhang, S; Wang, H; Kai, KL; Yao, CX; Dai, FF; Zhou, MJ; Li, JB; Wei, ZR; Yin, ZN; Zhu, WG; Xue, LX; Zang, MX				Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Wang, Hao; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Wei, Zhi-Ru; Yin, Zhongnan; Zhu, Wei-Guo; Xue, Lixiang; Zang, Ming-Xi			A GRIP-1-EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a	ONCOGENE			English	Article							CYCLIN D1; DIFFERENTIATION; EXPRESSION; POLYCOMB; PROLIFERATION; PATHOGENESIS; PAX3-FOXO1; REPRESSES; GROWTH; CELLS	Terminal differentiation failure is an important cause of rhabdomyosarcoma genesis, however, little is known about the epigenetic regulation of aberrant myogenic differentiation. Here, we show that GATA-4 recruits polycomb group proteins such as EZH2 to negatively regulate miR-29a in undifferentiated C2C12 myoblast cells, whereas recruitment of GRIP-1 to GATA-4 proteins displaces EZH2, resulting in the activation of miR-29a during myogenic differentiation of C2C12 cells. Moreover, in poorly differentiated rhabdomyosarcoma cells, EZH2 still binds to the miR-29a promoter with GATA-4 to mediate transcriptional repression of miR-29a. Interestingly, once re-differentiation of rhabdomyosarcoma cells toward skeletal muscle, EZH2 was dispelled from miR-29a promoter which is similar to that in myogenic differentiation of C2C12 cells. Eventually, this expression of miR-29a results in limited rhabdomyosarcoma cell proliferation and promotes myogenic differentiation. We thus establish that GATA-4 can function as a molecular switch in the up- and downregulation of miR-29a expression. We also demonstrate that GATA-4 acts as a tumor suppressor in rhabdomyosarcoma partly via miR-29a, which thus provides a potential therapeutic target for rhabdomyosarcoma.	[Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Zang, Ming-Xi] Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China; [Wang, Hao; Yin, Zhongnan; Xue, Lixiang] Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China; [Wei, Zhi-Ru] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhu, Wei-Guo] Shenzhen Univ, Dept Biochem & Mol Biol, Sch Med, Shenzhen 518055, Peoples R China; [Xue, Lixiang] Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China	Zhengzhou University; Zhengzhou University; Shenzhen University	Zang, MX (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China.	lixiangxue@hsc.pku.edu.cn; mzang@zzu.edu.cn			National Natural Science Foundation of China [82072975, 81771631, 81672091, 91749107]; High-Level Talents of Henan Province; Central Plains Basic Research [ZYQR201810120]; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020 [XKZDQY202002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High-Level Talents of Henan Province; Central Plains Basic Research; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020	This study was supported by the National Natural Science Foundation of China (No. 82072975, 81771631, 81672091, and 91749107), the High-Level Talents of Henan Province, particularly the support for the Central Plains Thousand Talents Program, which are the leading talents of Central Plains Basic Research (ZYQR201810120), 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines), and the key project of discipline construction of Zhengzhou University in 2020 (XKZDQY202002).	Achour C, 2018, FRONT BIOSCI-LANDMRK, V23, P2106, DOI 10.2741/4693; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Ballarino M, 2016, J CLIN INVEST, V126, P2021, DOI 10.1172/JCI84419; Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709; Bevilacqua A, 2014, CARDIOVASC PATHOL, V23, P85, DOI 10.1016/j.carpath.2013.09.003; Cai R, 2018, J BIOL CHEM, V293, P19177, DOI 10.1074/jbc.RA118.003198; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01458; Chen SL, 2000, GENE DEV, V14, P1209; Chikenji A, 2016, J ORAL SCI, V58, P219, DOI 10.2334/josnusd.15-0684; Chinenov Y, 2012, P NATL ACAD SCI USA, V109, P11776, DOI 10.1073/pnas.1206059109; Ciesla M, 2014, INT J BIOCHEM CELL B, V53, P482, DOI 10.1016/j.biocel.2014.05.003; Dai XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0485-1; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DiPiazza ARC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100699118; Hanna JA, 2018, ONCOGENE, V37, P1991, DOI 10.1038/s41388-017-0081-3; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Healy E, 2019, MOL CELL, V76, P437, DOI 10.1016/j.molcel.2019.08.012; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kouznetsova VL, 2019, PROTEIN SCI, V28, P1387, DOI 10.1002/pro.3647; Ma CX, 2015, CELL MOL LIFE SCI, V72, P2005, DOI 10.1007/s00018-014-1795-9; Megiorni F, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102673; Mikhailov AT, 2016, HEART FAIL REV, V21, P783, DOI 10.1007/s10741-016-9569-0; Missiaglia E, 2017, CANCER LETT, V385, P251, DOI 10.1016/j.canlet.2016.10.011; Pandey PR, 2017, J PATHOL, V241, P626, DOI 10.1002/path.4867; Qiu H, 2016, CELL DEATH DIFFER, V23, P1658, DOI 10.1038/cdd.2016.56; Qu Y, 2016, NUCLEIC ACIDS RES, V44, P7659, DOI 10.1093/nar/gkw463; Schwartz YB, 2014, CELL REP, V8, P321, DOI 10.1016/j.celrep.2014.07.001; Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225; Vella S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0107-z; Vu LP, 2013, INT J HEMATOL, V97, P198, DOI 10.1007/s12185-012-1247-y; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wannenes F, 2008, MOL CELL ENDOCRINOL, V292, P11, DOI 10.1016/j.mce.2008.05.018; Wei W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.184; Whitcomb J, 2020, IUBMB LIFE, V72, P53, DOI 10.1002/iub.2163; Xiong CJ, 2013, J CELL BIOCHEM, V114, P2708, DOI 10.1002/jcb.24619; Yao CX, 2015, J CELL BIOCHEM, V116, P1755, DOI 10.1002/jcb.25134; Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370; Yao CX, 2012, J MOL BIOL, V415, P143, DOI 10.1016/j.jmb.2011.11.011; Zhang S, 2019, J CELL PHYSIOL, V234, P13252, DOI 10.1002/jcp.27997	43	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5223	5237		10.1038/s41388-022-02521-5	http://dx.doi.org/10.1038/s41388-022-02521-5		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36309571				2022-12-26	WOS:000875805200001
J	Unlu, B; Kocaturk, B; Rondon, AMR; Lewis, CS; Swier, N; van den Akker, RFP; Krijgsman, D; Noordhoek, I; Blok, EJ; Bogdanov, VY; Ruf, W; Kuppen, PJK; Versteeg, HH				Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Lewis, Clayton S.; Swier, Nathalie; van den Akker, Rob F. P.; Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Bogdanov, Vladimir Y.; Ruf, Wolfram; Kuppen, Peter J. K.; Versteeg, Henri H.			Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer	ONCOGENE			English	Article							FACTOR EXPRESSION; CELLS; PROGNOSIS; CARCINOMA; EMT; COAGULATION; MECHANISMS; TRANSITION; INSIGHTS; THERAPY	Tissue Factor (TF) is the initiator of blood coagulation but also functions as a signal transduction receptor. TF expression in breast cancer is associated with higher tumor grade, metastasis and poor survival. The role of TF signaling on the early phases of metastasis has never been addressed. Here, we show an association between TF expression and metastasis as well as cancer stemness in 574 breast cancer patients. In preclinical models, blockade of TF signaling inhibited metastasis tenfold independent of primary tumor growth. TF blockade caused a reduction in epithelial-to-mesenchymal-transition, cancer stemness and expression of the pro-metastatic markers Slug and SOX9 in several breast cancer cell lines and in ex vivo cultured tumor cells. Mechanistically, TF forms a complex with beta 1-integrin leading to inactivation of beta 1-integrin. Inhibition of TF signaling induces a shift in TF-binding from alpha 3 beta 1-integrin to alpha 6 beta 4 and dictates FAK recruitment, leading to reduced epithelial-to-mesenchymal-transition and tumor cell differentiation. In conclusion, TF signaling inhibition leads to reduced pro-metastatic transcriptional programs, and a subsequent integrin beta 1 and beta 4-dependent reduction in metastasic dissemination.	[Unlu, Betul; Kocaturk, Begum; Rondon, Araci M. R.; Swier, Nathalie; van den Akker, Rob F. P.; Versteeg, Henri H.] Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands; [Lewis, Clayton S.; Bogdanov, Vladimir Y.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH USA; [Krijgsman, Danielle; Noordhoek, Iris; Blok, Erik J.; Kuppen, Peter J. K.] Leiden Univ, Dept Surg, Med Ctr, Leiden, Netherlands; [Ruf, Wolfram] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA; [Ruf, Wolfram] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Med Ctr, Mainz, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University System of Ohio; University of Cincinnati; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute; Johannes Gutenberg University of Mainz	Versteeg, HH (corresponding author), Leiden Univ, Dept Internal Med, Einthoven Lab Expt Vasc Med, Med Ctr, Leiden, Netherlands.	h.h.versteeg@lumc.nl	; Unlu, Betul/L-2048-2018	Rondon, Araci M R/0000-0002-2703-8805; Unlu, Betul/0000-0001-5587-4176	Dutch Cancer Society [UL 2015-7594]; Netherlands Organization for Scientific Research [VIDI 91710329]; Worldwide Cancer Research [15-1186]; NIH/NCI [R01CA190717]	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Worldwide Cancer Research; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Dutch Cancer Society (UL 2015-7594), The Netherlands Organization for Scientific Research (VIDI 91710329) and Worldwide Cancer Research (15-1186). VYB and CSL are partially supported by the NIH/NCI (grant R01CA190717).	Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Beaver CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089834; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Chen QK, 2013, DIFFERENTIATION, V86, P126, DOI 10.1016/j.diff.2013.03.003; DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Garg M, 2017, WORLD J STEM CELLS, V9, P118, DOI 10.4252/wjsc.v9.i8.118; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Ishiwata T, 2016, PATHOL INT, V66, P601, DOI 10.1111/pin.12447; Jessani N, 2004, P NATL ACAD SCI USA, V101, P13756, DOI 10.1073/pnas.0404727101; Kim KJ, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030032; Kocaturk B, 2013, J THROMB HAEMOST, V11, P285, DOI 10.1111/jth.12222; Kocaturk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967; Kocaturk B, 2013, P NATL ACAD SCI USA, V110, P11517, DOI 10.1073/pnas.1307100110; Kotiyal S, 2014, BIOCHEM BIOPH RES CO, V453, P112, DOI 10.1016/j.bbrc.2014.09.069; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Levy S, 2005, PHYSIOLOGY, V20, P218, DOI 10.1152/physiol.00015.2005; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Nitori N, 2005, CLIN CANCER RES, V11, P2531, DOI 10.1158/1078-0432.CCR-04-0866; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Paula AD, 2017, ANTICANCER RES, V37, P2173, DOI 10.21873/anticanres.11552; Richards JO, 2016, CANCER IMMUNOL IMMUN, V65, P1325, DOI 10.1007/s00262-016-1885-7; Rothmeier AS, 2018, BLOOD, V131, P674, DOI 10.1182/blood-2017-02-768218; Ryden L, 2010, INT J CANCER, V126, P2330, DOI 10.1002/ijc.24921; Sawada M, 1999, BRIT J CANCER, V79, P472, DOI 10.1038/sj.bjc.6690073; Schaffner F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061071; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shaker H, 2017, ONCOTARGET, V8, P25915, DOI 10.18632/oncotarget.13928; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; STURM U, 1992, VIRCHOWS ARCH A, V421, P79, DOI 10.1007/BF01607039; Teplyakov A, 2017, CELL SIGNAL, V36, P139, DOI 10.1016/j.cellsig.2017.05.004; Ueno T, 2000, BRIT J CANCER, V83, P164; Unlu B, 2017, THROMB RES, V156, P1, DOI 10.1016/j.thromres.2017.05.028; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van den Berg YW, 2012, BLOOD, V119, P924, DOI 10.1182/blood-2011-06-317685; van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7; Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048; Yamashita H, 2007, J SURG ONCOL, V95, P324, DOI 10.1002/jso.20680; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang XS, 2017, ONCOTARGET, V8, P59086, DOI 10.18632/oncotarget.19175	51	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5176	5185		10.1038/s41388-022-02511-7	http://dx.doi.org/10.1038/s41388-022-02511-7		OCT 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271029	Bronze			2022-12-26	WOS:000870984500003
J	Zhang, LC; Wang, LF; Xiang, SY; Hu, YY; Zhao, SY; Liao, Y; Zhu, ZF; Wu, XY				Zhang, Lichao; Wang, Lifu; Xiang, Suoyu; Hu, Yunyi; Zhao, Siyu; Liao, Yao; Zhu, Zifeng; Wu, Xiaoying			CRISPR/Cas9-mediated gene knockout of Sj16 in Schistosoma japonicum eggs upregulates the host-to-egg immune response	FASEB JOURNAL			English	Article						CRISPR/Cas9; IL-1 beta; Schistosoma japonicum; Sj16; T-cell immunity	IFN-GAMMA; CELLS; INFLAMMATION; PROTEIN; RSJ16; SUPPRESSION; IL-1-BETA; WORMS; IL-4	Schistosomiasis is an important, neglected tropical disease. Schistosoma japonicum can evade host attacks by regulating the host's immunity, causing continuous infection. However, interactions between the host's immune system and S. japonicum are unclear. Our previous research found that the Sj16 protein isolated from S. japonicum has an anti-inflammatory effect in the host. However, the role of Sj16 in the regulation of host immunity in S. japonicum infection is not clear. Here, we applied the CRISPR/Cas9 technique to knockout Sj16 in S. japonicum eggs and investigated the effect of Sj16 in regulating host immunity. We found egg viability decreased after Sj16 knockout. In addition, we found granulomatous inflammation increased, the T-cell immune response enhanced and the immune microenvironment changed in mice model injected with Sj16-knockout eggs by tail vein. These findings suggested that S. japonicum could regulate host immunity through Sj16 to evade the host immune attack and cause continuous infection. In addition, we confirmed the application of CRISPR/Cas9-mediated gene reprogramming for functional genomics in S. japonicum.	[Zhang, Lichao; Wang, Lifu; Xiang, Suoyu; Hu, Yunyi; Zhao, Siyu; Liao, Yao; Zhu, Zifeng; Wu, Xiaoying] Sun Yat Sen Univ, Dept Parasitol Zhongshan, Sch Med, Guangzhou, Peoples R China; [Zhang, Lichao; Xiang, Suoyu; Hu, Yunyi; Zhao, Siyu; Liao, Yao; Zhu, Zifeng] Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou, Peoples R China; [Zhang, Lichao; Xiang, Suoyu; Hu, Yunyi; Zhao, Siyu; Liao, Yao; Zhu, Zifeng] Pmvincial Engn Technol Res Ctr Biol Vector Contro, Guangzhou, Peoples R China; [Wang, Lifu] Guangzhou Med Univ, KingMed Sch Lab Med, Guangzhou Key Lab Clin Rapid Diag & Early Warning, Guangzhou, Peoples R China; [Wu, Xiaoying] Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 3, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen University	Wu, XY (corresponding author), Sun Yat Sen Univ, Dept Gastroenterol, Affiliated Hosp 3, Guangzhou, Peoples R China.	wuxy227@mail.sysu.edu.cn			National Natural Science Foundation of China (NSFC) [81871682, 81902081]; Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) [2020A1515011573]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)(National Natural Science Foundation of Guangdong Province)	National Natural Science Foundation of China (NSFC), Grant/Award Number: 81871682 and 81902081; Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation), Grant/Award Number: 2020A1515011573	Anders HJ, 2016, J AM SOC NEPHROL, V27, P2564, DOI 10.1681/ASN.2016020177; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Barnett R, 2018, LANCET, V392, P2431, DOI 10.1016/S0140-6736(18)33008-3; Braun MC, 2000, J IMMUNOL, V164, P3009, DOI 10.4049/jimmunol.164.6.3009; Campanati A, 2014, ARCH DERMATOL RES, V306, P915, DOI 10.1007/s00403-014-1493-3; Chen DH, 2016, IMMUNOLOGY, V149, P25, DOI 10.1111/imm.12623; Cheng YL, 2008, PARASITOL RES, V102, P1129, DOI 10.1007/s00436-008-0880-0; Cui J, 2014, HUM VACC IMMUNOTHER, V10, P3270, DOI 10.4161/21645515.2014.979640; Degboe Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00003; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; Dong BL, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006237; Dunne DW, 2005, NAT REV IMMUNOL, V5, P420, DOI 10.1038/nri1601; Gao YN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082480; Gobert GN, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-128; Gray DJ, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2651; Hosokawa I, 2016, INFLAMMATION, V39, P1520, DOI 10.1007/s10753-016-0386-3; Hu SM, 2012, J PARASITOL, V98, P274, DOI 10.1645/GE-2692.1; Hu SM, 2009, INT J PARASITOL, V39, P191, DOI 10.1016/j.ijpara.2008.06.017; Ittiprasert W, 2019, ELIFE, V8, DOI 10.7554/eLife.41337; Jenkins SJ, 2005, PARASITE IMMUNOL, V27, P385, DOI 10.1111/j.1365-3024.2005.00789.x; Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196; Kogan-Sakin I, 2009, CARCINOGENESIS, V30, P698, DOI 10.1093/carcin/bgp043; Kong DL, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3729-8; Li XH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003925; Liu X, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00732-19; Lu LX, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1010596; Lu LX, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008909; Lu YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08689-1; Lundy SK, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00039; Mahnke K, 2005, CURR TOP MICROBIOL, V293, P133, DOI 10.1007/3-540-27702-1_7; Masamba P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137216; McManus DP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0013-8; Santana JB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.605235; Schwartz C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02492; Shen J, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3697-z; Sun X, 2010, PARASITE IMMUNOL, V32, P739, DOI 10.1111/j.1365-3024.2010.01240.x; Sun XJ, 2012, PARASITE IMMUNOL, V34, P430, DOI 10.1111/j.1365-3024.2012.01377.x; Sun X, 2012, PARASITOL RES, V110, P2429, DOI 10.1007/s00436-011-2782-9; Tallima H, 2009, CYTOKINE, V48, P239, DOI 10.1016/j.cyto.2009.07.581; Uchiyama R, 2017, J IMMUNOL, V199, P1122, DOI 10.4049/jimmunol.1601373; Vennervald BJ, 2004, CURR OPIN INFECT DIS, V17, P439, DOI 10.1097/00001432-200410000-00009; Wang JP, 2020, SCIENCE, V369, P1649, DOI 10.1126/science.abb7699; Wang LF, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10219; Wang LF, 2017, THERANOSTICS, V7, P3446, DOI 10.7150/thno.20359; WARREN KS, 1975, AM J PATHOL, V80, P279; Wendt G, 2020, SCIENCE, V369, P1644, DOI 10.1126/science.abb7709; Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x; Xie H, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.617461; You H, 2021, FASEB J, V35, DOI 10.1096/fj.202001745RR; Zhang AP, 2020, CELL IMMUNOL, V352, DOI 10.1016/j.cellimm.2020.104113; Zhang YM, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-05006-8; Zhang YX, 2012, EUR J IMMUNOL, V42, P1523, DOI 10.1002/eji.201141933; Zheng B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00061; Zhou S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005094	55	0	0	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22615	10.1096/fj.202200600RR	http://dx.doi.org/10.1096/fj.202200600RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5M6JH	36273308				2022-12-26	WOS:000871204600001
J	Bao, LT; Karpenko, VV; Forster, AC				Bao, Letian; Karpenko, Victoriia V.; Forster, Anthony C.			Rate-limiting hydrolysis in ribosomal release reactions revealed by ester activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; GGQ MOTIF; PEPTIDYL; SITE; TRANSLATION		[Bao, Letian; Karpenko, Victoriia V.; Forster, Anthony C.] Uppsala Univ, Dept Cell & Mol Biol, Uppsala, Sweden	Uppsala University	Forster, AC (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Uppsala, Sweden.	a.forster@icm.uu.se			Swedish Research Council;  [2017-04148]	Swedish Research Council(Swedish Research CouncilEuropean Commission); 	Funding and additional information - This work was supported by the Swedish Research Council (NT project grant 2017-04148 to A. C. F.) .	Amort M, 2007, NUCLEIC ACIDS RES, V35, P5130, DOI 10.1093/nar/gkm539; CASKEY CT, 1971, P NATL ACAD SCI USA, V68, P3163, DOI 10.1073/pnas.68.12.3163; Doerfel LK, 2015, J AM CHEM SOC, V137, P12997, DOI 10.1021/jacs.5b07427; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Fu ZA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10608-z; Indrisiunaite G, 2015, J MOL BIOL, V427, P1848, DOI 10.1016/j.jmb.2015.01.007; Jin H, 2010, P NATL ACAD SCI USA, V107, P8593, DOI 10.1073/pnas.1003995107; Johansson M, 2011, P NATL ACAD SCI USA, V108, P79, DOI 10.1073/pnas.1012612107; Kazemi M, 2016, ACS CATAL, V6, P8432, DOI 10.1021/acscatal.6b02842; Kuhlenkoetter S, 2011, NATURE, V476, P351, DOI 10.1038/nature10247; Kwiatkowski M, 2014, BIOCONJUGATE CHEM, V25, P2086, DOI 10.1021/bc500441b; Liljeruhm J, 2019, ACS CHEM BIOL, V14, P204, DOI 10.1021/acschembio.8b00952; Loh PG, 2010, CURR OPIN STRUC BIOL, V20, P98, DOI 10.1016/j.sbi.2009.12.005; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Pundir S, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100681; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Shaw JJ, 2007, MOL CELL, V28, P458, DOI 10.1016/j.molcel.2007.09.007; Simonovic M, 2008, RNA, V14, P2372, DOI 10.1261/rna.1118908; Vogel C, 2020, ENG REP, V2, DOI 10.1002/eng2.12126; Wang JF, 2016, J AM CHEM SOC, V138, P15587, DOI 10.1021/jacs.6b06936; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Zaher HS, 2011, EMBO J, V30, P2445, DOI 10.1038/emboj.2011.142; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zhang BL, 2007, J AM CHEM SOC, V129, P11316, DOI 10.1021/ja073487l	24	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11								10.1016/j.jbc.2022.102509	http://dx.doi.org/10.1016/j.jbc.2022.102509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36300356	gold, Green Published			2022-12-26	WOS:000886086000012
J	Wu, DB; Xiang, L; Peng, LL; Gu, HT; Tang, YH; Luo, HY; Liu, H; Wang, YX				Wu, Dabin; Xiang, Ling; Peng, Linglong; Gu, Haitao; Tang, Yunhao; Luo, Haoyun; Liu, Hang; Wang, Yaxu			Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma	PLOS ONE			English	Article							ACID-BINDING PROTEINS; SUPPRESSES PROLIFERATION; CANCER; CELLS	Background Fatty acid-binding protein 4 (FABP4) has been reported to be associated with tumor progress and poor prognosis in various cancers. However, the relationship between FABP4 expression and tumor immunity in colon adenocarcinoma (COAD) is still poorly understood. Methods FABP4 mRNA expression was analyzed using The Cancer Genome Atlas (TCGA)-COAD data. FABP4 protein staining was performed by immunohistochemistry (IHC) staining in our 10 paired COAD samples and corresponding adjacent noncancerous tissues. The association between FABP4 and immune cell infiltration was evaluated by Tumor Immune Estimation Resource (TIMER) database. FABP4 coexpressed genes were identified based on Cancer Cell Line Encyclopedia (CCLE) database, which were employed for further enrichment analysis. FABP4 related immunomodulators was identified by Tumor and Immune System Interaction Database (TISIDB) database, and a prognostic risk signature was constructed based on FABP4-related immunomodulators using stepwise Cox regression analysis. A nomogram consists of FABP4 related immunomodulators signature and clinical parameters was developed to predict the overall survival (OS). Results In TCGA data, we found that the decreased FABP4 mRNA expression in COAD samples compared with normal samples, and low FABP4 mRNA expression was associated with B cells, CD4+ T cells, CD8+ T cells, myeloid dendritic cells, macrophages, and neutrophils. In our 10 paired samples, the protein levels of COAD were lower in all COAD tissues than in their adjacent noncancerous tissues. Functional enrichment analysis revealed that FABP4 coexpressed genes were mostly enriched in immune-related pathways. Based on 54 FABP4-related immunomodulators, a 2-gene FABP4-related prognostic risk signature was developed, and the signature stratified the patients into the high-risk and low-risk groups with statistically different survival outcomes. The Nomogram consists of the prognostic signature and clinical parameters had a certain predictability for prognosis of COAD patients. Conclusion These findings suggest that FABP4 is associated with 2-gene immune signature which also correlate with the prognosis of COAD patients.	[Wu, Dabin; Peng, Linglong; Gu, Haitao; Tang, Yunhao; Luo, Haoyun; Liu, Hang; Wang, Yaxu] Chongqing Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 2, Chongqing, Peoples R China; [Xiang, Ling] Chongqing Med Univ, Dept Clin Nutr, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Wang, YX (corresponding author), Chongqing Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 2, Chongqing, Peoples R China.	300897@hospital.cqmu.edu.cn		wang, yaxu/0000-0002-4466-5675	General Project of Chongqing Natural Science Foundation; Chongqing Science and Technology Commission, China [cstc2021jcyj-msxmX0153]; The Kuanren Talents Program of The Second Affiliated Hospital of Chongqing Medical University [kryc-yq-2110]	General Project of Chongqing Natural Science Foundation; Chongqing Science and Technology Commission, China(Natural Science Foundation Project of CQ CSTC); The Kuanren Talents Program of The Second Affiliated Hospital of Chongqing Medical University	This work was supported by The General Project of Chongqing Natural Science Foundation, Chongqing Science and Technology Commission, China (cstc2021jcyj-msxmX0153), and The Kuanren Talents Program of The Second Affiliated Hospital of Chongqing Medical University (kryc-yq-2110). Funders play a role in data collection and analysis.	Bao XW, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001437; Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Choi I, 2011, J BIOMED INFORM, V44, P595, DOI 10.1016/j.jbi.2011.02.005; Cui YJ, 2019, PATHOL INT, V69, P68, DOI 10.1111/pin.12756; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Gerada C, 2020, MOL ONCOL, V14, P1913, DOI 10.1002/1878-0261.12774; Guaita-Esteruelas S, 2017, MOL CARCINOGEN, V56, P208, DOI 10.1002/mc.22485; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao JQ, 2018, CANCER RES, V78, P2343, DOI 10.1158/0008-5472.CAN-17-2465; Harjes U, 2017, ONCOGENE, V36, P912, DOI 10.1038/onc.2016.256; Jhunjhunwala S, 2021, NAT REV CANCER, V21, P298, DOI 10.1038/s41568-021-00339-z; Karlsson M, 2010, ANN SURG ONCOL, V17, P1747, DOI 10.1245/s10434-010-0920-8; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Lee MY, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001111; Li BL, 2017, JAMA ONCOL, V3, P1529, DOI 10.1001/jamaoncol.2017.1609; Li GQ, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02273-4; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li XY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01678; Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618; Liu YS, 2021, CANCER MED-US, V10, P2112, DOI 10.1002/cam4.3678; Ru BB, 2019, BIOINFORMATICS, V35, P4200, DOI 10.1093/bioinformatics/btz210; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Thumser AE, 2014, CURR OPIN CLIN NUTR, V17, P124, DOI 10.1097/MCO.0000000000000031; Wu ZM, 2021, ONCOTARGETS THER, V14, P3929, DOI 10.2147/OTT.S311792; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhong CQ, 2018, CANCER MED-US, V7, P2629, DOI 10.1002/cam4.1511; Zhuang GJ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.591079	28	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2022	17	10							e0276430	10.1371/journal.pone.0276430	http://dx.doi.org/10.1371/journal.pone.0276430			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6V9VQ	36264920	Green Published, gold			2022-12-26	WOS:000895386200001
J	Wang, YN; Ruan, DY; Wang, ZX; Yu, K; Rong, DL; Liu, ZX; Wang, F; Hu, JJ; Jin, Y; Wu, QN; Pu, HY; Wang, M; Xu, RH; Zeng, ZL				Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Rong, Dai-Lin; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei			Targeting the cholesterol-ROR alpha/gamma axis inhibits colorectal cancer progression through degrading c-myc	ONCOGENE			English	Article							ORPHAN NUCLEAR RECEPTORS; DOUBLE-BLIND; CELL-PROLIFERATION; PHASE-III; ALPHA; METABOLISM; MULTICENTER; SIMVASTATIN; OXYSTEROLS; SURVIVAL	Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on the cholesterol-nuclear receptors (NRs) axis as a strategy. Cholesterol and its derivatives work as ligands for different nuclear receptors, thus promoting cancer progression. The key NR downstream of cholesterol in CRC is unknown. Here, we treated CRC cells with a cholesterol-lowering agent and lipoprotein-depleted conditioned medium, and then detected the change of the putative NRs. The results revealed that ROR alpha/gamma (Retinoic acid receptor-related Orphan Receptor alpha/gamma) levels exhibited the most obvious increases in CRC cells subjected them to cholesterol deprivation. ROR alpha/gamma agonists significantly inhibited CRC cells proliferation and migration in vitro and in vivo. Also, ROR alpha/gamma overexpression repressed CRC cells proliferation and migration in vitro and in vivo and ROR alpha/gamma knockdown promoted it. Mechanistically, ROR alpha/gamma agonists promoted c-myc degradation by activating the transcription of the ubiquitinase NEDD4. Intriguingly, the combination of ROR alpha/gamma agonists and atorvastatin had a synergistic effect on inhibiting CRC cells. These findings demonstrate that the cholesterol- ROR alpha/gamma axis is important for maintaining c-myc protein levels. Combination therapy with atorvastatin and ROR alpha/gamma agonist is a promising therapeutic strategy for CRC.	[Wang, Ying-Nan; Wang, Zi-Xian; Wang, Feng; Jin, Ying; Xu, Rui-Hua] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China; [Ruan, Dan-Yun] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Clin Res, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Yu, Kai; Liu, Ze-Xian; Hu, Jia-Jia; Pu, Heng-Ying; Wang, Min; Zeng, Zhao-Lei] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Rong, Dai-Lin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Wu, Qi-Nian] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China	Xu, RH (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Xu, RH; Zeng, ZL (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China.; Zeng, ZL (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn; zengzhl@sysucc.org.cn			National Natural Science Foundation of China [81930065, 82173128, 81903163, 82072612]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]; Natural Science Foundation of Guangdong Province [2019A1515010233]; China Postdoctoral Science Foundation [2020M673000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81930065, 82173128, 81903163, 82072612), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), the Natural Science Foundation of Guangdong Province (2019A1515010233), and the China Postdoctoral Science Foundation (2020M673000).	Adhyaru BB, 2018, NAT REV CARDIOL, V15, P757, DOI 10.1038/s41569-018-0098-5; Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758; Bardou M, 2010, GUT, V59, P1572, DOI 10.1136/gut.2009.190900; Bovenga F, 2015, CELL METAB, V21, P517, DOI 10.1016/j.cmet.2015.03.002; Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2; Brown AJ, 2021, BRIT J PHARMACOL, V178, P3089, DOI 10.1111/bph.15073; Buren S, 2016, CANCER CELL, V30, P290, DOI 10.1016/j.ccell.2016.06.023; Cai DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12529-3; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng CM, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0301-4; Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586-019-0920-1; Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438; Dejure FR, 2017, EMBO J, V36, P1854, DOI 10.15252/embj.201796662; Dobrzycka M, 2020, EXP CLIN ENDOCR DIAB, V128, P255, DOI 10.1055/a-0668-5692; Du J, 2012, INT J MOL SCI, V13, P15755, DOI 10.3390/ijms131215755; Duffy MJ, 2021, CANCER TREAT REV, V94, DOI 10.1016/j.ctrv.2021.102154; Fan JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01187; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Hadjiphilippou S, 2019, CIRC RES, V124, P354, DOI 10.1161/CIRCRESAHA.118.313245; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kim H, 2011, MOL CELL, V44, P797, DOI 10.1016/j.molcel.2011.09.023; Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Liu J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15112-3; Ma LQ, 2019, MOL CELL ENDOCRINOL, V484, P42, DOI 10.1016/j.mce.2019.01.016; Marciano DP, 2014, CELL METAB, V19, P193, DOI 10.1016/j.cmet.2013.12.009; Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Qiu RM, 2018, J MED CHEM, V61, P5794, DOI 10.1021/acs.jmedchem.7b01314; Raza S, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0422-x; Rene O, 2015, ACS MED CHEM LETT, V6, P276, DOI 10.1021/ml500420y; Riscal R, 2019, MOL CELL, V76, P220, DOI 10.1016/j.molcel.2019.09.008; Roshan-Moniri M, 2014, CANCER TREAT REV, V40, P1137, DOI 10.1016/j.ctrv.2014.10.005; Seckl MJ, 2017, J CLIN ONCOL, V35, P1506, DOI 10.1200/JCO.2016.69.7391; Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098; Silvente-Poirot S, 2018, CANCER RES, V78, P4803, DOI [10.1158/0008-5472.CAN-18-1487, 10.1158/0008-5472.can-18-1487]; Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Tian Y, 2015, PUBLIC HEALTH NUTR, V18, P3355, DOI 10.1017/S1368980015000646; Villa GR, 2016, CANCER CELL, V30, P683, DOI 10.1016/j.ccell.2016.09.008; Wang C, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00500-y; Wang JJ, 2016, NAT MED, V22, P488, DOI 10.1038/nm.4070; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Ward NC, 2019, CIRC RES, V124, P328, DOI 10.1161/CIRCRESAHA.118.312782; Xiao L, 2015, AM J PHYSIOL-CELL PH, V308, pC385, DOI 10.1152/ajpcell.00091.2014; Xiong GF, 2014, MOL CELL BIOL, V34, P3066, DOI 10.1128/MCB.00279-14; Xiong GF, 2012, CANCER RES, V72, P1728, DOI 10.1158/0008-5472.CAN-11-2762	57	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5266	5278		10.1038/s41388-022-02515-3	http://dx.doi.org/10.1038/s41388-022-02515-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316442	hybrid, Green Published			2022-12-26	WOS:000876857500002
J	Lakshmanan, I; Marimuthu, S; Chaudhary, S; Seshacharyulu, P; Rachagani, S; Muniyan, S; Chirravuri-Venkata, R; Atri, P; Rauth, S; Nimmakayala, RK; Siddiqui, JA; Gautam, SK; Shah, A; Natarajan, G; Parte, S; Bhyravbhatla, N; Mallya, K; Haridas, D; Talmon, GA; Smith, LM; Kumar, S; Ganti, AK; Jain, M; Ponnusamy, MP; Batra, SK				Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Talmon, Geoffrey A.; Smith, Lynette M.; Kumar, Sushil; Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.			Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER-CELLS; JAK2	MUC16, membrane-bound mucin, plays an oncogenic role in pancreatic ductal adenocarcinoma (PDAC). However, the pathological role of MUC16 in the PDAC progression, tumor microenvironment, and metastasis in cooperation with Kras(G12D) and Trp53(R172H) mutations remains unknown. Deletion of Muc16 with activating mutations Kras(G12D/+) and Trp53(R172H/+) in mice significantly decreased progression and prolonged overall survival in Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre; Muc16(-/-) (KPCM) and Kras(G12D/+); Pdx-1-Cre; Muc16(-/-) (KCM), as compared to Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre (KPC) and Kras(G12D/+); Pdx-1-Cre (KC) mice, respectively. Muc16 knockout pancreatic tumor (KPCM) displays decreased tumor microenvironment factors and significantly reduced incidence of liver and lung metastasis compared to KPC. Furthermore, in silico data analysis showed a positive correlation of MUC16 with activated stroma and metastasis-associated genes. KPCM mouse syngeneic cells had significantly lower metastatic and endothelial cell binding abilities than KPC cells. Similarly, KPCM organoids significantly decreased the growth rate compared to KPC organoids. Interestingly, RNA-seq data revealed that the cytoskeletal proteins Actg2, Myh11, and Pdlim3 were downregulated in KPCM tumors. Further knockdown of these genes showed reduced metastatic potential. Overall, our results demonstrate that Muc16 alters the tumor microenvironment factors during pancreatic cancer progression and metastasis by changing the expression of Actg2, Myh11, and Pdlim3 genes.	[Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Kumar, Sushil; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Talmon, Geoffrey A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Ganti, Apar Kishor] VA Nebraska Western Iowa Hlth Care Syst, Div Oncol Hematol, Dept Internal Med, Omaha, NE 68105 USA; [Ganti, Apar Kishor] Univ Nebraska Med Ctr, Omaha, NE 68105 USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	mpalanim@unmc.edu; sbatra@unmc.edu	Parte, Seema C/AAT-5014-2021; Nimmakayala, Rama Krishna/CAG-5670-2022	Parte, Seema C/0000-0002-2879-9534; Nimmakayala, Rama Krishna/0000-0003-4637-4828; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Chaudhary, Sanjib/0000-0001-9630-1235; Muniyan, Sakthivel/0000-0001-9405-7857	National Institutes of Health [P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, U01 CA210240]; Nebraska Department of Health and Human Services [LB595]; US Department of Veterans Affairs [I01 BX004676]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services; US Department of Veterans Affairs(US Department of Veterans Affairs)	We thank Dr. Richard R. Behringer, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, for providing the Muc16 whole-body knockout (C57BL/6J) mice. We thank Corinn Grabow for all the technical support. We thank the University of Nebraska Medical Center core facilities such as Advanced Microscopy Core Facility, Genomics Core Facility, and Tissue Science Facility. This work was, in parts, supported by the support from the National Institutes of Health P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, and U01 CA210240, and the Nebraska Department of Health and Human Services LB595, US Department of Veterans Affairs (I01 BX004676).	Akita K, 2013, EUR J CELL BIOL, V92, P257, DOI 10.1016/j.ejcb.2013.10.005; Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Belisle JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-118; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Buscail L, 2020, NAT REV GASTRO HEPAT, V17, P153, DOI 10.1038/s41575-019-0245-4; Caffrey T, 2019, FEBS LETT, V593, P2751, DOI 10.1002/1873-3468.13532; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chen SH, 2012, FASEB J, V26, P1349, DOI 10.1096/fj.11-195669; Cheon DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004675; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010; Das S, 2015, CANCER RES, V75, P4669, DOI 10.1158/0008-5472.CAN-15-1050; Das S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09759; Das S, 2015, ONCOTARGET, V6, P5772, DOI 10.18632/oncotarget.3308; Encarnacion-Rosado J, 2021, NAT REV GASTRO HEPAT, V18, P482, DOI 10.1038/s41575-021-00431-7; Felder M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-129; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hingorani SR, 2018, J CLIN ONCOL, V36, P359, DOI 10.1200/JCO.2017.74.9564; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kaushik G, 2021, ONCOGENE, V40, P848, DOI 10.1038/s41388-020-01564-w; Lakshmanan I, 2016, ONCOGENE, V35, P4112, DOI 10.1038/onc.2015.478; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lakshmanan I, 2017, CLIN CANCER RES, V23, P3906, DOI 10.1158/1078-0432.CCR-16-2530; Lakshmanan I, 2015, ONCOTARGET, V6, P21085, DOI 10.18632/oncotarget.3912; Lee Jae W, 2016, Curr Protoc Pharmacol, V73, DOI 10.1002/cpph.2; Lennon S, 2019, CLIN CANCER RES, V25, P3352, DOI 10.1158/1078-0432.CCR-18-2811; Li GL, 2003, J IMMUNOL, V171, P669, DOI 10.4049/jimmunol.171.2.669; Mallya K, 2020, BIOL OPEN, V9, DOI 10.1242/bio.052878; Marimuthu S, 2022, MOL CANCER RES, V20, P1208, DOI 10.1158/1541-7786.MCR-21-0888; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Muniyan Sakthivel, 2016, Genes Cancer, V7, P110, DOI 10.18632/genesandcancer.104; Nallasamy P, 2021, GASTROENTEROLOGY, V161, P1998, DOI 10.1053/j.gastro.2021.08.023; Nimmakayala RK, 2021, ONCOGENE, V40, P215, DOI 10.1038/s41388-020-01518-2; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Rauth S, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188527; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sperb N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155486; Tian CX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22490-9; Tian CX, 2019, P NATL ACAD SCI USA, V116, P19609, DOI 10.1073/pnas.1908626116; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169	45	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5147	5159		10.1038/s41388-022-02493-6	http://dx.doi.org/10.1038/s41388-022-02493-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271032				2022-12-26	WOS:000870984500004
J	Mitra, R; Nersesyan, A; Pentland, K; Melin, MM; Levy, RM; Ebong, EE				Mitra, Ronodeep; Nersesyan, Alina; Pentland, Kaleigh; Melin, M. Mark; Levy, Robert M.; Ebong, Eno E.			Diosmin and its glycocalyx restorative and anti-inflammatory effects on injured blood vessels	FASEB JOURNAL			English	Article						diosmin; endothelial dysfunction; endothelial glycocalyx; endothelium functionality; glycocalyx regeneration; vascular homeostasis	ENDOTHELIAL GLYCOCALYX; NITRIC-OXIDE; BARRIER PROPERTIES; CAROTID-ARTERY; IN-VIVO; INFLAMMATION; MODEL; MOUSE; FLOW; ATHEROSCLEROSIS	The endothelium, a crucial homeostatic organ, regulates vascular permeability and tone. Under physiological conditions, endothelial stimulation induces vasodilator endothelial nitric oxide (eNO) release and prevents adhesion molecule accessibility and leukocyte adhesion and migration into vessel walls. Endothelium dysfunction is a principal event in cardiovascular disorders, including atherosclerosis. Minimal attention is given to an important endothelial cell structure, the endothelial glycocalyx (GCX), a negatively charged heterogeneous polysaccharide that serves as a protective covering for endothelial cells and enables endothelial cells to transduce mechanical stimuli into various biological and chemical activities. Endothelial GCX shedding thus plays a role in endothelial dysfunction, for example by increasing vascular permeability and decreasing vessel tone. Consequently, there is increasing interest in developing therapies that focus on GCX repair to limit downstream endothelium dysfunction and prevent further downstream cardiovascular events. Here, we present diosmin (3 ',5,7-trihydroxy-4 '-methoxyflavone-7-rhamnoglucoside), a flavone glycoside of diosmetin, which downregulates adhesive molecule expression, decreases inflammation and capillary permeability, and upregulates eNO expression. Due to these pleiotropic effects of diosmin on the vasculature, a possible unidentified mechanism of action is through GCX restoration. We hypothesize that diosmin positively affects GCX integrity along with GCX-related endothelial functions. Our hypothesis was tested in a partial ligation left carotid artery (LCA) mouse model, where the right carotid artery was the control for each mouse. Diosmin (50 mg/kg) was administered daily for 7 days, 72 h after ligation. Within the ligated mice LCAs, diosmin treatment elevated the activated eNO synthase level, inhibited inflammatory cell uptake, decreased vessel wall thickness, increased vessel diameter, and increased GCX coverage of the vessel wall. ELISA showed a decrease in hyaluronan concentration in plasma samples of diosmin-treated mice, signifying reduced GCX shedding. In summary, diosmin supported endothelial GCX integrity, to which we attribute diosmin's preservation of endothelial function as indicated by attenuated expression of inflammatory factors and restored vascular tone.	[Mitra, Ronodeep; Pentland, Kaleigh; Ebong, Eno E.] Northeastern Univ, Dept Chem Engn, 805 Columbus Ave, Boston, MA 02120 USA; [Nersesyan, Alina; Ebong, Eno E.] Northeastern Univ, Dept Bioengn, Boston, MA 02120 USA; [Melin, M. Mark] M Hlth Fairview Wound Healing Inst, Edina, MN USA; [Levy, Robert M.] Primus Pharmaceut Inc, Clin Dev, Scottsdale, AZ USA; [Ebong, Eno E.] Albert Einstein Coll Med, Dept Neurosci, New York, NY USA	Northeastern University; Northeastern University; Yeshiva University	Ebong, EE (corresponding author), Northeastern Univ, Dept Chem Engn, 805 Columbus Ave, Boston, MA 02120 USA.	e.ebong@northeastern.edu		Melin, Matthew/0000-0002-1368-0426	National Institutes of Health (NIH) [K01 HL125499]; Primus Pharmaceuticals	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Primus Pharmaceuticals	HHS vertical bar National Institutes of Health (NIH), Grant/Award Number: K01 HL125499; Primus Pharmaceuticals	Abdel-Daim MM, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3281670; Al Shoyaib A, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-019-2745-x; Campanero MA, 2010, J PHARMACEUT BIOMED, V51, P875, DOI 10.1016/j.jpba.2009.09.012; Annecke T, 2011, BRIT J ANAESTH, V107, P679, DOI 10.1093/bja/aer269; Banerjee S, 2021, IND ENG CHEM RES, V60, P17328, DOI 10.1021/acs.iecr.1c03074; Bergan JJ, 2001, ANGIOLOGY, V52, pS43, DOI 10.1177/0003319701052001S06; Berkoz M, 2019, GEN PHYSIOL BIOPHYS, V38, P315, DOI 10.4149/gpb_2019010; Boisnic S, 2018, J COSMET DERMATOL-US, V17, P848, DOI 10.1111/jocd.12778; Cancel LM, 2016, ATHEROSCLEROSIS, V252, P136, DOI 10.1016/j.atherosclerosis.2016.07.930; Cao RN, 2019, CHINESE MED J-PEKING, V132, P963, DOI 10.1097/CM9.0000000000000177; Chappell D, 2009, BASIC RES CARDIOL, V104, P78, DOI 10.1007/s00395-008-0749-5; Cheng LS, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070672; Cheng MJ, 2016, INT J NANOMED, V11, P3305, DOI 10.2147/IJN.S106299; Chung S, 2020, FOOD SCI NUTR, V8, P5976, DOI 10.1002/fsn3.1883; Crespo ME, 1999, PLANTA MED, V65, P651, DOI 10.1055/s-2006-960838; Daniels BA., 2013, THERAPEUTIC SULFATED; Dogne S, 2020, AM J PATHOL, V190, P768, DOI 10.1016/j.ajpath.2019.11.016; Forstermann U, 2006, CIRCULATION, V113, P1708, DOI 10.1161/CIRCULATIONAHA.105.602532; Freag MS, 2013, INT J PHARMACEUT, V454, P462, DOI 10.1016/j.ijpharm.2013.06.039; Friesenecker B, 1995, INT J MICROCIRC, V15, P17, DOI 10.1159/000179090; Fuster JJ, 2012, PROG MOL BIOL TRANSL, V105, P1, DOI 10.1016/B978-0-12-394596-9.00001-9; Guevara RB, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00031-20; Harding IC, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1721-2; Hassan AA, 2018, PAK J PHARM SCI, V31, P1191; HENDERSON AH, 1991, BRIT HEART J, V65, P116; Henry CBS, 2000, AM J PHYSIOL-HEART C, V279, pH2815, DOI 10.1152/ajpheart.2000.279.6.H2815; Hermann Matthias, 2006, J Clin Hypertens (Greenwich), V8, P17, DOI 10.1111/j.1524-6175.2006.06032.x; Hippensteel JA, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2534-2; Itskovich VV, 2003, MAGNET RESON MED, V49, P381, DOI 10.1002/mrm.10360; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Katsenis Konstantinos, 2005, Current Vascular Pharmacology, V3, P1, DOI 10.2174/1570161052773870; Kolarova H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/694312; Korshunov VA, 2003, ARTERIOSCL THROM VAS, V23, P2185, DOI 10.1161/01.ATV.0000103120.06092.14; Kumase F, 2010, ACTA MED OKAYAMA, V64, P277; Kuzlan M, 1997, PERITON DIALYSIS INT, V17, P295; Li TJ, 2017, ONCOTARGET, V8, P91350, DOI 10.18632/oncotarget.20518; Lipowsky HH, 2012, ANN BIOMED ENG, V40, P840, DOI 10.1007/s10439-011-0427-x; Long RM., 2016, U.S. Patent, Patent No. [US20160296603A1, 20160296603]; Machin DR., 2019, FASEB J, V33; Mastantuono T, 2015, MICROCIRCULATION, V22, P378, DOI 10.1111/micc.12207; Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4; Mensah SA, 2020, FASEB J, V34, P6166, DOI 10.1096/fj.201901920R; Mensah SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186116; Mitra Ronodeep, 2018, Transl Med Commun, V3, DOI 10.1186/s41231-018-0029-9; Mitra R, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0691-9; MONSIGNY M, 1979, EUR J BIOCHEM, V98, P39, DOI 10.1111/j.1432-1033.1979.tb13157.x; Nam Douglas, 2010, J Vis Exp, DOI 10.3791/1861; Nam D, 2009, AM J PHYSIOL-HEART C, V297, pH1535, DOI 10.1152/ajpheart.00510.2009; Nemes KB, 2000, J PHARM PHARMACOL, V52, P47, DOI 10.1211/0022357001773670; Offeddu GS, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01774-2; Padberg JS, 2014, ATHEROSCLEROSIS, V234, P335, DOI 10.1016/j.atherosclerosis.2014.03.016; Park SA, 2020, BIOMOL THER, V28, P542, DOI 10.4062/biomolther.2020.135; Potter DR, 2009, CIRC RES, V104, P1318, DOI 10.1161/CIRCRESAHA.108.191585; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; Rahbar E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0481-5; Ramani VC, 2012, J BIOL CHEM, V287, P9952, DOI 10.1074/jbc.M111.330803; Ramelet AA, 2001, ANGIOLOGY, V52, pS49, DOI 10.1177/0003319701052001S07; Russo R, 2018, MOLECULES, V23, DOI 10.3390/molecules23092174; Ryva B, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00100; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]; Schwartz BG, 2010, INT J IMPOT RES, V22, P77, DOI 10.1038/ijir.2009.59; Sciences CH., 2019, ARTEROSIL ARTERY SUP; Senthamizhselvan O, 2014, EUR J PHARMACOL, V736, P131, DOI 10.1016/j.ejphar.2014.04.026; Serra H, 2008, BIOORGAN MED CHEM, V16, P4009, DOI 10.1016/j.bmc.2008.01.028; Shabani S, 2018, BIOMED PHARMACOTHER, V108, P1376, DOI 10.1016/j.biopha.2018.09.127; Shalkami AS, 2018, HUM EXP TOXICOL, V37, P78, DOI 10.1177/0960327117694075; Silambarasan T, 2012, EUR J PHARMACOL, V679, P81, DOI 10.1016/j.ejphar.2011.12.040; Smith C, 1999, J VASC RES, V36, P24, DOI 10.1159/000054071; Sullivan CJ, 2002, ARTERIOSCL THROM VAS, V22, P1100, DOI 10.1161/01.ATV.0000023230.17493.E3; Tarbell JM, 2016, J INTERN MED, V280, P97, DOI 10.1111/joim.12465; Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x; Tarbell JM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.140pt8; Tessari P, 2010, DIABETES, V59, P2152, DOI 10.2337/db09-1772; Tong NT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061794; Uchimido R, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2292-6; Ushiyama A, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0182-z; Vafa A, 2020, HUM EXP TOXICOL, V39, P1133, DOI 10.1177/0960327119889655; van den Berg BM, 2009, PFLUG ARCH EUR J PHY, V457, P1199, DOI 10.1007/s00424-008-0590-6; VanTeeffelen JW, 2007, TRENDS CARDIOVAS MED, V17, P101, DOI 10.1016/j.tcm.2007.02.002; VanTeeffelen JWGE, 2007, HYPERTENSION, V50, P261, DOI 10.1161/HYPERTENSIONAHA.107.089250; Vink H, 2000, CIRCULATION, V101, P1500, DOI 10.1161/01.CIR.101.13.1500; Wang GQ, 2020, ARTERIOSCL THROM VAS, V40, P350, DOI 10.1161/ATVBAHA.119.313399; Yang J, 2012, J CHROMATOGR B, V898, P95, DOI 10.1016/j.jchromb.2012.04.024; Yen WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117133; Zaragoza C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/497841; Zeng Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086249; Zhang R, 2015, BIOTECHNOL LETT, V37, P1257, DOI 10.1007/s10529-015-1792-6; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	88	0	0	2	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2022	36	12							e22630	10.1096/fj.202200053RR	http://dx.doi.org/10.1096/fj.202200053RR			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5U5CO	36315163				2022-12-26	WOS:000876565000001
J	Ma, ML; Zhang, CH; Cao, R; Tang, DM; Sang, XB; Zou, SL; Wang, XX; Xu, HX; Liu, G; Dai, LZ; Tian, Y; Gao, X; Fu, XH				Ma, Meilin; Zhang, Changhui; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Wang, Xiuxuan; Xu, Haixia; Liu, Geng; Dai, Lunzhi; Tian, Yan; Gao, Xiang; Fu, Xianghui			UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; QUALITY-CONTROL; E2 ENZYMES; EXPRESSION	Cancer cells rely on heightened protein quality control mechanisms, including the ubiquitin-proteosome system that is predominantly driven by ubiquitination comprising E1, E2, and E3 trienzyme cascades. Although E3s have been extensively studied, the implication of E2s in tumorigenesis is poorly defined. Here we reveal a critical E2 in the pathogenesis of hepatocellular carcinoma (HCC). Among all of E2s, UBE2O shows the strongest association with HCC survival prognosis, and its expression is increased in HCC tumors. Accordingly, UBE2O deficiency inhibits HCC growth and metastasis both in vitro and in vivo, while its overexpression has opposite effects. Depending on both E2 and E3 enzymatic activities, UBE2O can interact with and mediate the ubiquitination and degradation of HADHA, a mitochondrial beta-oxidation enzyme, thereby modulating lipid metabolic reprogramming. HADHA is reduced in HCC tumors and inversely correlated with UBE2O levels. Importantly, HADHA acts as a tumor suppressor and primarily mediates UBE2O's function on HCC. Moreover, liver-specific deletion of Ube2o in mice are resistant to DEN-induced hepatocarcinogenesis, along with HADHA upregulation and reduced hepatic lipid accumulation. These data reveal UBE2O as a novel oncogenic driver for metabolic reprogramming and HCC development, highlighting the potential of targeting UBE2O/HADHA axis for HCC therapy.	[Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Collaborat Innovat, Changchun 610041, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Collaborat Innovat, Changchun 610041, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.	xianggao@scu.edu.cn; xfu@scu.edu.cn			National Natural Science Foundation of China [82103128, 92157205, 81970561, 81802836]; National Key Research and Development Program of China [2018YFC2000305]; Ministry of Science and Technology of China [2018ZX09201018-005]; China National Postdoctoral Program for Innovative Talents [BX2021201]; China Postdoctoral Science Foundation [2021M692302]; 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University [ZYJC18049]; Sichuan Science & Technology Program [2019JDTD0013]; Post-Doctor Research Project, West China Hospital, Sichuan University [2020HXBH121]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Ministry of Science and Technology of China(Ministry of Science and Technology, China); China National Postdoctoral Program for Innovative Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University; Sichuan Science & Technology Program; Post-Doctor Research Project, West China Hospital, Sichuan University	This work was supported by the National Natural Science Foundation of China (82103128, 92157205, 81970561, and 81802836), the National Key Research and Development Program of China (2018YFC2000305), the Ministry of Science and Technology of China (2018ZX09201018-005), China National Postdoctoral Program for Innovative Talents (BX2021201), China Postdoctoral Science Foundation (2021M692302), the 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University (ZYJC18049), Sichuan Science & Technology Program (2019JDTD0013), and the Post-Doctor Research Project, West China Hospital, Sichuan University (2020HXBH121).	Amoedo ND, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI133081; Chen SP, 2018, J BIOL CHEM, V293, P11296, DOI 10.1074/jbc.RA117.001432; Chi ZX, 2020, MOL CELL, V80, P43, DOI 10.1016/j.molcel.2020.08.015; Costa-Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Faust TB, 2018, ELIFE, V7, DOI 10.7554/eLife.31879; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051; Huang YM, 2021, CELL DEATH DIFFER, V28, P671, DOI 10.1038/s41418-020-00616-8; Khare T, 2020, INT J CANCER, V147, P1461, DOI 10.1002/ijc.32943; Kim Y, 2016, NAT PROTOC, V11, P937, DOI 10.1038/nprot.2016.050; Lectez B, 2014, J PROTEOME RES, V13, P3016, DOI 10.1021/pr5001913; Liang KW, 2017, CELL, V168, P59, DOI 10.1016/j.cell.2016.12.011; Lim HY, 2013, ANN SURG ONCOL, V20, P3747, DOI 10.1245/s10434-013-3070-y; Liu J, 2022, THERANOSTICS, V12, P1342, DOI 10.7150/thno.65778; Liu S, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111558; Liu XM, 2020, HEPATOLOGY, V72, P2029, DOI 10.1002/hep.31222; Liu X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2194-9; Liu YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14190-2; Liu Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0841-3; Ljubkovic M, 2019, DIABETES, V68, P1924, DOI 10.2337/db19-0423; Ma ML, 2019, HEPATOLOGY, V70, P215, DOI 10.1002/hep.30602; Mashtalir N, 2014, MOL CELL, V54, P392, DOI 10.1016/j.molcel.2014.03.002; McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288; Meng Z, 2017, ONCOGENE, V36, P2446, DOI 10.1038/onc.2016.400; Mi BB, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00624-3; Miklas JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12482-1; Minguez B, 2011, J HEPATOL, V55, P1325, DOI 10.1016/j.jhep.2011.02.034; Muto Y, 2019, J EXP MED, V216, P950, DOI 10.1084/jem.20180900; Nguyen AT, 2017, SCIENCE, V357, DOI 10.1126/science.aan0218; Osada T, 1997, J HEPATOL, V26, P1266, DOI 10.1016/S0168-8278(97)80461-8; Osborne HC, 2021, TRENDS CELL BIOL, V31, P628, DOI 10.1016/j.tcb.2021.01.009; Pan A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28044-x; Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769; Shi Z, 2021, INT J MED SCI, V18, P3749, DOI 10.7150/ijms.63220; Shirahashi H, 2002, LIVER, V22, P413, DOI 10.1034/j.1600-0676.2002.01541.x; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stewart MD, 2016, CELL RES, V26, P423, DOI 10.1038/cr.2016.35; Tanaka M, 2013, MOL MED REP, V7, P365, DOI 10.3892/mmr.2012.1201; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tian Y, 2022, MOL THER-NUCL ACIDS, V30, P1, DOI 10.1016/j.omtn.2022.08.036; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vila IK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128269; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Villa E, 2016, GUT, V65, P861, DOI 10.1136/gutjnl-2014-308483; Wang JX, 2019, J HEPATOL, V71, P742, DOI 10.1016/j.jhep.2019.05.027; Xia CW, 2019, P NATL ACAD SCI USA, V116, P6069, DOI 10.1073/pnas.1816317116; Xu HX, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000603; Xu H, 2019, EMBO J, V38, DOI 10.15252/embj.2019101996; Yamamoto K, 2020, LAB INVEST, V100, P353, DOI 10.1038/s41374-019-0318-6; Yanagitani K, 2017, SCIENCE, V357, P472, DOI 10.1126/science.aan0178; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Yokoyama Y, 2004, PROTEOMICS, V4, P2111, DOI 10.1002/pmic.200300712; Yu HS, 2020, HEPATOLOGY, V72, P518, DOI 10.1002/hep.31045; Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922	56	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5199	5213		10.1038/s41388-022-02509-1	http://dx.doi.org/10.1038/s41388-022-02509-1		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36273042				2022-12-26	WOS:000871165700001
J	Mo, ZG; Qian, L; Yao, TZ; Gao, YP; Xue, FJ; Zhang, JH; Zhang, R; Liu, EL				Mo, Zuguo; Qian, Li; Yao, Tianzhi; Gao, Yunpeng; Xue, Fujun; Zhang, Jianhai; Zhang, Ru; Liu, Enlong			Unified transient creep constitutive model based on the crack evolution of micritic bioclastic limestone	PLOS ONE			English	Article							RHEOLOGICAL MODEL; ROCK; BEHAVIOR; SALT; TESTS; TERM; LAW	The surrounding rock at the exit of the No. 1 drainage tunnel of the Artashi Water Conservancy Project is micritic bioclastic limestone with 55% bioclastic material. This rock underwent unpredictable large and time-dependent deformation during excavation. To date, the mechanical behaviour of this kind of rock has rarely been studied. In this study, traditional triaxial compression tests and multilevel creep tests were conducted on micritic bioclastic limestone, and the results clarified the instantaneous and time-dependent mechanical properties of the rock. Considering that the essence of rock failure is crack growth, the crack strain evolution properties were revealed in rock triaxial compression tests and multilevel creep tests. Based on triaxial compression tests, the evolution of axial cracks with increasing deviatoric stress ratio Rd (ratio of deviatoric stress to peak deviatoric stress) was observed, and an axial crack closure element and new crack growth element were proposed. To simulate the creep behaviour of a rock specimen, the relationship of the rock creep crack strain rate with Rd was studied. A creep crack element was created, and the creep crack strain evolution equation was obtained, which closely fit the experimental data. Combining the 4 element types (elastic element, crack closure element, crack growth element, and creep crack element), a unified transient creep constitutive model (Mo's model) was proposed, which represented both the transient and time-dependent mechanical properties of the micritic bioclastic limestone.	[Mo, Zuguo; Qian, Li; Yao, Tianzhi; Gao, Yunpeng; Xue, Fujun; Zhang, Jianhai; Zhang, Ru; Liu, Enlong] Sichuan Univ, Coll Water Resources & Hydropower, State Key Lab Hydraul & Mt River Engn, Chengdu, Peoples R China	Sichuan University	Zhang, JH (corresponding author), Sichuan Univ, Coll Water Resources & Hydropower, State Key Lab Hydraul & Mt River Engn, Chengdu, Peoples R China.	zhangjianhai@scu.edu.com		Zhang, Jianhai/0000-0002-8670-5655	National Natural Science Foundation of China [U1965203]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Ru Zhang received funding in the form of a grant from National Natural Science Foundation of China (U1965203).	Aubertin M, 2000, INT J ROCK MECH MIN, V37, P1169, DOI 10.1016/S1365-1609(00)00047-2; Bieniawski ZT, 1967, INT J ROCK MECH MINI, V4, P407, DOI [DOI 10.1016/0148-9062(67)90031-9, 10.1016/0148-9062(67)90031-9]; BLAIR GWS, 1947, J COLL SCI IMP U TOK, V2, P21; BOUKHAROV GN, 1995, INT J ROCK MECH MIN, V32, P325, DOI 10.1016/0148-9062(94)00048-8; Brantut N, 2013, J STRUCT GEOL, V52, P17, DOI 10.1016/j.jsg.2013.03.007; Cao WG, 2020, COMPUT GEOTECH, V124, DOI 10.1016/j.compgeo.2020.103599; CHARLES RJ, 1958, J APPL PHYS, V29, P1554, DOI 10.1063/1.1722992; Chen CF, 2018, INT J ROCK MECH MIN, V112, P55, DOI 10.1016/j.ijrmms.2018.09.002; Eberhardt E, 1998, CAN GEOTECH J, V35, P222, DOI 10.1139/cgj-35-2-222; EL-Sorogy AS, 2016, J AFR EARTH SCI, V115, P63, DOI 10.1016/j.jafrearsci.2015.12.013; Fahimifar A, 2015, SOILS FOUND, V55, P1364, DOI 10.1016/j.sandf.2015.10.003; Huang X, 2022, ENERGIES, V15, DOI 10.3390/en15051885; JEFFREYS H, 1958, GEOPHYS J ROY ASTR S, V1, P92, DOI 10.1111/j.1365-246X.1958.tb00037.x; Ji Y, 2012, OIL GAS SCI TECHNOL, V67, P753, DOI 10.2516/ogst/2012051; Kachanov ML, 1982, MECH MATER, V1, P123, DOI 10.1016/0167-6636(82)90040-0; Li H, 2020, J PETROL SCI ENG, V185, DOI 10.1016/j.petrol.2019.106672; Li XZ, 2016, ENVIRON EARTH SCI, V75, DOI 10.1007/s12665-016-5365-3; Liu HF, 2021, ROCK MECH ROCK ENG, V54, P5591, DOI 10.1007/s00603-021-02570-4; Liu L, 2013, T NONFERR METAL SOC, V23, P478, DOI 10.1016/S1003-6326(13)62488-7; LOCKNER D, 1993, J GEOPHYS RES-SOL EA, V98, P475, DOI 10.1029/92JB01828; Lockner DA, 1998, J GEOPHYS RES-SOL EA, V103, P5107, DOI 10.1029/97JB03211; Lyu C, 2021, INT J ROCK MECH MIN, V146, DOI 10.1016/j.ijrmms.2021.104873; Martin CD, 1993, THESIS U MANITOBA WI; MARUYAMA K, 1990, J PRESS VESS-T ASME, V112, P92, DOI 10.1115/1.2928593; Meng QS, 2019, ROCK SOIL MECH, V40, P183, DOI 10.16285/j.rsm.2017.1271; Qian L, 2022, ENVIRON EARTH SCI, V81, DOI 10.1007/s12665-022-10241-y; Rozic B, 2019, SWISS J GEOSCI, V112, P163, DOI 10.1007/s00015-018-0320-9; Sharifzadeh M, 2013, TUNN UNDERGR SP TECH, V38, P348, DOI 10.1016/j.tust.2013.07.014; Singh A, 2018, INT J ROCK MECH MIN, V107, P243, DOI 10.1016/j.ijrmms.2018.04.037; Taheri A, 2020, CONSTR BUILD MATER, V243, DOI 10.1016/j.conbuildmat.2020.118263; Tomanovic Z, 2006, MECH TIME-DEPEND MAT, V10, P135, DOI 10.1007/s11043-006-9005-2; Vajdova V, 2012, J STRUCT GEOL, V43, P100, DOI 10.1016/j.jsg.2012.07.006; Vajdova V, 2010, J STRUCT GEOL, V32, P1158, DOI 10.1016/j.jsg.2010.07.007; VOGLER UW, 1978, INT J ROCK MECH MIN, V15, P47, DOI 10.1016/0148-9062(78)91677-7; Wang RF, 2019, INT J ROCK MECH MIN, V123, DOI 10.1016/j.ijrmms.2019.104087; Xu M, 2018, ACTA GEOTECH, V13, P1313, DOI 10.1007/s11440-018-0716-8; Zhang LY, 2020, ADV MATER SCI ENG, V2020, DOI 10.1155/2020/3576181; Zhang SG, 2019, RESULTS PHYS, V12, P1119, DOI 10.1016/j.rinp.2018.12.081; Zhang XP, 2021, ROCK MECH ROCK ENG, V54, P973, DOI 10.1007/s00603-020-02277-y; Zhang X, 2021, ARCH CIV MECH ENG, V21, DOI 10.1007/s43452-021-00224-4; Zhao J, 2019, ENG GEOL, V258, DOI 10.1016/j.enggeo.2019.105157; Zhao YL, 2019, THEOR APPL FRACT MEC, V101, P59, DOI 10.1016/j.tafmec.2019.01.026; Zhao YL, 2017, INT J ROCK MECH MIN, V93, P66, DOI 10.1016/j.ijrmms.2017.01.004; Zhou HW, 2013, MECH TIME-DEPEND MAT, V17, P413, DOI 10.1007/s11043-012-9193-x; Zhou HW, 2011, INT J ROCK MECH MIN, V48, P116, DOI 10.1016/j.ijrmms.2010.11.004; Zhou KF, 2022, GEOFLUIDS, V2022, DOI 10.1155/2022/3512507; Zhu CQ, 2016, OCEAN ENG, V114, P224, DOI 10.1016/j.oceaneng.2016.01.009; Zuo JP, 2019, J CENT SOUTH UNIV, V26, P3045, DOI 10.1007/s11771-019-4235-z	48	0	0	13	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2022	17	10							e0276100	10.1371/journal.pone.0276100	http://dx.doi.org/10.1371/journal.pone.0276100			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6W8UF	36301876	gold, Green Published			2022-12-26	WOS:000896001400001
J	Lee, LM; Christodoulou, EG; Shyamsunder, P; Chen, BJ; Lee, KL; Fung, TK; So, CWE; Wong, GC; Petretto, E; Rackham, OJL; Ong, ST				Lee, Lin Ming; Christodoulou, Eleni G.; Shyamsunder, Pavithra; Chen, Bei Jun; Lee, Kian Leong; Fung, Tsz Kan; So, Chi Wai Eric; Wong, Gee Chuan; Petretto, Enrico; Rackham, Owen J. L.; Tiong Ong, S.			A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify (R)	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PLURIPOTENT STEM-CELLS; GENOME-WIDE ANALYSIS; TRANS-RETINOIC ACID; SELF-RENEWAL; CHIP-SEQ; EXPRESSION; ALPHA; PML; TRANSCRIPTION	Acute myeloid leukaemia (AML) is a rapidly fatal blood cancer that is characterised by the accumulation of immature myeloid cells in the blood and bone marrow as a result of blocked differentiation. Methods which identify master transcriptional regulators of AML subtype-specific leukaemia cell states and their combinations could be critical for discovering novel differentiation-inducing therapies. In this proof-of-concept study, we demonstrate a novel utility of the Mogrify (R) algorithm in identifying combinations of transcription factors (TFs) and drugs, which recapitulate granulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line, using two different approaches. In the first approach, Connectivity Map (CMAP) analysis of these TFs and their target networks outperformed standard approaches, retrieving ATRA as the top hit. We identify dimaprit and mebendazole as a drug combination which induces myeloid differentiation. In the second approach, we show that genetic manipulation of specific Mogrify (R)-identified TFs (MYC and IRF1) leads to co-operative induction of APL differentiation, as does pharmacological targeting of these TFs using currently available compounds. We also show that loss of IRF1 blunts ATRA-mediated differentiation, and that MYC represses IRF1 expression through recruitment of PML-RARa, the driver fusion oncoprotein in APL, to the IRF1 promoter. Finally, we demonstrate that these drug combinations can also induce differentiation of primary patient-derived APL cells, and highlight the potential of targeting MYC and IRF1 in high-risk APL. Thus, these results suggest that Mogrify (R) could be used for drug discovery or repositioning in leukaemia differentiation therapy for other subtypes of leukaemia or cancers.	[Lee, Lin Ming; Shyamsunder, Pavithra; Lee, Kian Leong; Tiong Ong, S.] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore; [Christodoulou, Eleni G.; Chen, Bei Jun; Petretto, Enrico; Rackham, Owen J. L.] Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll London, Comprehens Canc Ctr, London, England; [Fung, Tsz Kan; So, Chi Wai Eric] Kings Coll Hosp London, Dept Haematol Med, London, England; [Wong, Gee Chuan; Tiong Ong, S.] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore; [Petretto, Enrico] Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England; [Petretto, Enrico] China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China; [Rackham, Owen J. L.] Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England; [Tiong Ong, S.] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore; [Tiong Ong, S.] Duke Univ, Dept Med, Med Ctr, Durham, NC USA	National University of Singapore; National University of Singapore; National University of Singapore; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Singapore General Hospital; Imperial College London; University of Southampton; National Cancer Centre Singapore (NCCS); Duke University	Ong, ST (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Ctr Computat Biol, Singapore, Singapore.; Petretto, E; Rackham, OJL (corresponding author), Duke NUS Med Sch, Programme Cardiovasc & Metab Disorders, Singapore, Singapore.; Ong, ST (corresponding author), Singapore Gen Hosp, Dept Haematol, Singapore, Singapore.; Petretto, E (corresponding author), Imperial Coll London, MRC London Inst Med Sci LMC, Fac Med, London, England.; Petretto, E (corresponding author), China Pharmaceut Univ CPU, Inst Big Data & Artificial Intelligence Med, Sch Sci, Nanjing, Peoples R China.; Rackham, OJL (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO17 1BJ, England.; Ong, ST (corresponding author), Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore.; Ong, ST (corresponding author), Duke Univ, Dept Med, Med Ctr, Durham, NC USA.	enrico.petretto@duke-nus.edu.sg; owen.rackham@duke-nus.edu.sg; sintiong.ong@duke-nus.edu.sg		Lee, Lin Ming/0000-0001-6229-3679	National Medical Research Council (NMRC) of Singapore [MOH-000059/MOH-CSASI18may-0002, NMRC/CIRG/1429/2015]; NMRC YIRG [NMRC/OFYIRG/0022/2016]; Singapore National Research Foundation grant [NRF-CRP20-2017-0002]	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore); NMRC YIRG; Singapore National Research Foundation grant(National Research Foundation, Singapore)	The authors would like to acknowledge Dr. Sonia P. Chothani for providing the RNA-Seq data analysis pipeline, the ssCMAP developer, Dr. Shu-Dong Zhang, for helpful discussion on the algorithm's internal calculations, the Duke-NUS Genome Biology Facility (DGBF) for RNA, ChIP-and ATAC-sequencing services, as well as Dr. Gee Chuan Wong/Bryan Y.W. Teo, SGH Department of Haematology for providing primary APL samples. This work was funded by the National Medical Research Council (NMRC) of Singapore (MOH-000059/MOH-CSASI18may-0002) and NMRC/CIRG/1429/2015 to STO). OJLR is supported by NMRC YIRG (NMRC/OFYIRG/0022/2016) and by a Singapore National Research Foundation grant [NRF-CRP20-2017-0002].	Assi SA, 2019, NAT GENET, V51, P151, DOI 10.1038/s41588-018-0270-1; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Brodsky A, 1998, EUR J PHARMACOL, V350, P121, DOI 10.1016/S0014-2999(98)00227-1; Cao ZD, 2021, MOL CELL, V81, P3604, DOI 10.1016/j.molcel.2021.07.018; Chao MP, 2017, CELL STEM CELL, V20, P329, DOI 10.1016/j.stem.2016.11.018; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Coccia EM, 2001, BIOCHEM J, V360, P285, DOI 10.1042/0264-6021:3600285; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; de The H, 2017, CANCER CELL, V32, P552, DOI 10.1016/j.ccell.2017.10.002; dos Santos GA, 2013, J EXP MED, V210, P2793, DOI 10.1084/jem.20131121; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Fiedler K, 2012, AM J BLOOD RES, V2, P57; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Gao TS, 2016, BIOINFORMATICS, V32, P3543, DOI 10.1093/bioinformatics/btw495; Gonda TJ, 2015, NAT REV CANCER, V15, P686, DOI 10.1038/nrc4018; Hu MH, 2018, J MED CHEM, V61, P2447, DOI 10.1021/acs.jmedchem.7b01697; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; KALINYAK KA, 1985, LIFE SCI, V36, P1909, DOI 10.1016/0024-3205(85)90439-4; Khwaja A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.10; Kotini AG, 2017, CELL STEM CELL, V20, P315, DOI 10.1016/j.stem.2017.01.009; Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501; Leon J, 2009, CELL CYCLE, V8, P1148, DOI 10.4161/cc.8.8.8126; Li YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53290-3; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin XJ, 2021, CLIN CANCER RES, V27, P3683, DOI 10.1158/1078-0432.CCR-20-4375; Liu QY, 2015, MOL PHARMACOL, V88, P469, DOI 10.1124/mol.115.097915; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lourenco C, 2021, NAT REV CANCER, V21, P579, DOI 10.1038/s41568-021-00367-9; Lucena-Araujo AR, 2019, BLOOD, V132, P951, DOI 10.1182/blood.2019000239; McClellan JS, 2015, P NATL ACAD SCI USA, V112, P4074, DOI 10.1073/pnas.1413383112; McNamara S, 2008, MOL CELL BIOL, V28, P2066, DOI 10.1128/MCB.01576-07; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Michalska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01135; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Ng KP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205254; Nichol JN, 2016, CELL REP, V14, P2938, DOI 10.1016/j.celrep.2016.02.074; Norsworthy KJ, 2016, CURR OPIN HEMATOL, V23, P127, DOI 10.1097/MOH.0000000000000215; Padmanabhan A, 2013, J BIOL CHEM, V288, P14158, DOI 10.1074/jbc.M112.432377; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Pantziarka P, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.443; Park SM, 2019, CELL STEM CELL, V24, P153, DOI 10.1016/j.stem.2018.10.016; Paul F, 2016, CELL, V164, P325, DOI 10.1016/j.cell.2015.12.046; Prunier C, 2015, CELL REP, V10, P883, DOI 10.1016/j.celrep.2015.01.024; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200/JCO.2008.18.6130; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sapio L, 2017, J CELL PHYSIOL, V232, P922, DOI 10.1002/jcp.25650; SAWUTZ DG, 1984, J PHARMACOL EXP THER, V231, P1; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shayo C, 1997, MOL PHARMACOL, V51, P983, DOI 10.1124/mol.51.6.983; Shi LH, 2011, GENE, V487, P21, DOI 10.1016/j.gene.2011.07.004; Shyamsunder P, 2019, BLOOD, V133, P2507, DOI 10.1182/blood.2018886077; Si JL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-92; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan Y, 2021, BLOOD, V137, P1503, DOI 10.1182/blood.2020005698; Testa U, 2004, LEUKEMIA, V18, P1864, DOI 10.1038/sj.leu.2403472; Testa U, 2016, ANN HEMATOL, V95, P673, DOI 10.1007/s00277-016-2622-1; Vicente C, 2012, CRIT REV ONCOL HEMAT, V82, P1, DOI 10.1016/j.critrevonc.2011.04.007; Walf-Vorderwulbecke V, 2018, LEUKEMIA, V32, P882, DOI 10.1038/leu.2017.317; Wang E, 2021, CELL STEM CELL, V28, P718, DOI 10.1016/j.stem.2020.12.005; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang P., 2020, GENOME BIOL, V21; Yang LJ, 2003, J MOL DIAGN, V5, P212, DOI 10.1016/S1525-1578(10)60476-X; Yun HY, 2021, NAT GENET, V53, P1443, DOI 10.1038/s41588-021-00925-9; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang L, 2020, BLOOD, V135, P1133, DOI 10.1182/blood.2019001863; Zhang SD, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-258; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102	79	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5160	5175		10.1038/s41388-022-02505-5	http://dx.doi.org/10.1038/s41388-022-02505-5		OCT 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271030	Bronze			2022-12-26	WOS:000870984500001
J	Zhang, QQ; Gao, YR; Zhang, YX; Jing, MR; Wang, D; Wang, YZ; Khattak, S; Qi, HW; Cai, CB; Zhang, J; Ngowi, EE; Khan, NH; Li, T; Ji, AL; Jiang, QY; Ji, XY; Li, YZ; Wu, DD				Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong			Cystathionine gamma-lyase mediates cell proliferation, migration, and invasion of nasopharyngeal carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ENDOGENOUS HYDROGEN-SULFIDE; HUMAN PROSTATE-CANCER; PROMOTES; H2S; PI3K/AKT/MTOR; SUPPRESSES; MODULATION; MECHANISMS; PATHWAY	Nasopharyngeal carcinoma (NPC) is an epithelia-derived malignancy with a distinctive geographic distribution. Cystathionine gamma-lyase (CSE) is involved in cancer development and progression. Nevertheless, the role of CSE in the growth of NPC is unknown. In this study, we found that CSE levels in human NPC cells were higher than those in normal nasopharyngeal cells. CSE overexpression enhanced the proliferative, migrative, and invasive abilities of NPC cells and CSE downregulation exerted reverse effects. Overexpression of CSE decreased the expressions of cytochrome C, cleaved caspase (cas)-3, cleaved cas-9, and cleaved poly-ADP-ribose polymerase, whereas CSE knockdown exhibited reverse effects. CSE overexpression decreased reactive oxygen species (ROS) levels and the expressions of phospho (p)-extracellular signal-regulated protein kinase 1/2, p-c-Jun N-terminal kinase, and p-p38, but promoted the expressions of p-phosphatidylinositol 3-kinase (PI3K), p-AKT, and p-mammalian target of rapamycin (mTOR), whereas CSE knockdown showed oppose effects. In addition, CSE overexpression promoted NPC xenograft tumor growth and CSE knockdown decreased tumor growth by modulating proliferation, angiogenesis, cell cycle, and apoptosis. Furthermore, DL-propargylglycine (an inhibitor of CSE) dose-dependently inhibited NPC cell growth via ROS-mediated mitogen-activated protein kinase (MAPK) and PI3K/AKT/mTOR pathways without significant toxicity. In conclusion, CSE could regulate the growth of NPC cells through ROS-mediated MAPK and PI3K/AKT/mTOR cascades. CSE might be a novel tumor marker for the diagnosis and prognosis of NPC. Novel donors/drugs that inhibit the expression/activity of CSE can be developed in the treatment of NPC.	[Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China; [Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China; [Khattak, Saadullah; Khan, Nazeer Hussain] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto; Ji, Xinying] Henan Univ, Henan Prov Engn Ctr Tumor Mol Med, Kaifeng Municipal Key Lab Cell Signal Transduct, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto] Dar Es Salaam Univ, Fac Sci, Dept Biol Sci, Coll Educ, Dar Es Salaam 2329, Tanzania; [Wu, Dongdong] Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China	Henan University; Henan University; Henan University; Henan University; University of Dar es Salaam; Henan University	Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China.; Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China.; Wu, DD (corresponding author), Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China.	10190096@vip.henu.edu.cn; yanzhang206@163.com; ddwubiomed2010@163.com	Wu, Dongdong/GQP-4472-2022	Wu, Dongdong/0000-0001-6739-8437	National Natural Science Foundation of China [81802718, U1504817]; Foundation of Science & Technology Department of Henan Province, China [202102310480, 192102310151]; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China [2020GGJS038]; Science Foundation for Young Talents of Henan University College of Medicine, China [2019013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Science & Technology Department of Henan Province, China; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China; Science Foundation for Young Talents of Henan University College of Medicine, China	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802718, U1504817), the Foundation of Science & Technology Department of Henan Province, China (Nos. 202102310480, 192102310151), the Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China (No. 2020GGJS038), and the Science Foundation for Young Talents of Henan University College of Medicine, China (No. 2019013).	Ascencao K, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2020.105393; Augsburger F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030447; Beneke S, 2004, INT J CANCER, V111, P813, DOI 10.1002/ijc.20342; Breza J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4508-1; Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846; Chakraborty PK, 2018, FASEB J, V32, P4145, DOI 10.1096/fj.201701095R; Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]; Chen MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35468; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Dong Q, 2019, CANCER LETT, V455, P60, DOI 10.1016/j.canlet.2019.04.031; Fan CD, 2017, CELL MOL NEUROBIOL, V37, P211, DOI 10.1007/s10571-016-0362-3; Fan K, 2014, CELL SIGNAL, V26, P2801, DOI 10.1016/j.cellsig.2014.08.023; Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205; Fu DA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.582273; George BP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6797921; Giovinazzo D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017225118; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han JM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052473; Hartle MD, 2016, CHEM SOC REV, V45, P6108, DOI 10.1039/c6cs00212a; Hsu HY, 2018, CANCER LETT, V432, P112, DOI 10.1016/j.canlet.2018.05.006; Hu YQ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4764071; Jiang CM, 2017, ARCH ORAL BIOL, V74, P108, DOI 10.1016/j.archoralbio.2016.11.016; Julien O, 2017, CELL DEATH DIFFER, V24, P1380, DOI 10.1038/cdd.2017.44; Jurkowska H, 2011, AMINO ACIDS, V41, P151, DOI 10.1007/s00726-010-0606-3; Ke LR, 2017, P NATL ACAD SCI USA, V114, P9683, DOI 10.1073/pnas.1705236114; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Li WP, 2021, CANCER LETT, V499, P301, DOI 10.1016/j.canlet.2020.11.001; Li WW, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4690857; Luo M, 2019, CANCER LETT, V455, P26, DOI 10.1016/j.canlet.2019.04.019; Lv HH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5021983; Martinez-Cutillas M, 2015, PHARMACOL RES, V93, P52, DOI 10.1016/j.phrs.2015.01.002; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan Y, 2014, MUTAT RES-FUND MOL M, V763, P10, DOI 10.1016/j.mrfmmm.2014.03.002; Panza E, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12312; Pei YX, 2011, TOXICOL APPL PHARM, V257, P420, DOI 10.1016/j.taap.2011.09.026; Phillips CM, 2017, CANCER RES, V77, P5741, DOI 10.1158/0008-5472.CAN-16-3480; Pitchakarn P, 2011, CANCER LETT, V306, P142, DOI 10.1016/j.canlet.2011.02.041; Pupo E, 2011, FREE RADICAL BIO MED, V51, P1765, DOI 10.1016/j.freeradbiomed.2011.08.007; Sekiguchi F, 2016, BIOL PHARM BULL, V39, P887, DOI 10.1248/bpb.b15-01015; Shan BE, 2016, ONCOL REP, V36, P1551, DOI 10.3892/or.2016.4938; Shen Q, 2018, HEPATOLOGY, V67, P1360, DOI 10.1002/hep.29606; Shibuya N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2371; Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507; Sur S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111455; Szabo C, 2017, PHARMACOL REV, V69, P497, DOI 10.1124/pr.117.014050; Szabo C, 2016, NAT REV DRUG DISCOV, V15, P185, DOI 10.1038/nrd.2015.1; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433; Wang J, 2020, INT J MED SCI, V17, P1499, DOI 10.7150/ijms.47024; Wang LP, 2019, INT J ONCOL, V55, P473, DOI 10.3892/ijo.2019.4823; Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011; Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18; Wang YH, 2019, EMBO REP, V20, DOI 10.15252/embr.201845986; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3831713; Wu DD, 2019, J CELL MOL MED, V23, P1698, DOI 10.1111/jcmm.14065; Wu DD, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4391-9; Wu DD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.585860; Wu DD, 2019, MOL BIOL REP, V46, P2665, DOI 10.1007/s11033-019-04698-7; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6927298; Wu DD, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0762-9; Wu DD, 2015, NITRIC OXIDE-BIOL CH, V50, P38, DOI 10.1016/j.niox.2015.08.004; Wu DD, 2014, CANCER LETT, V351, P13, DOI 10.1016/j.canlet.2014.05.002; Xiao Q, 2020, J DERMATOL SCI, V98, P26, DOI 10.1016/j.jdermsci.2020.02.004; Xiao Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01463-w; Xie YY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113429; Xu YJ, 2019, CANCER LETT, V447, P33, DOI 10.1016/j.canlet.2019.01.022; Ye F, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118348; Youness RA, 2021, J ADV RES, V27, P177, DOI 10.1016/j.jare.2020.07.006; Zeng Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1807-7; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zhao LF, 2015, BIOL CHEM, V396, P1247, DOI 10.1515/hsz-2015-0148; Zhao YW, 2018, BIOMED PHARMACOTHER, V98, P36, DOI 10.1016/j.biopha.2017.12.029; Zhu LS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5905-9	75	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5238	5252		10.1038/s41388-022-02512-6	http://dx.doi.org/10.1038/s41388-022-02512-6		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36310322	Green Submitted			2022-12-26	WOS:000876210600001
J	Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn, SCD; Landolfi, S; Hernandez-Losa, J; Schwartz, S; Matias-Guiu, X; Cajal, SRY; Martinez-Barriocanal, A; Arango, D				Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Tarragona, Jordi; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Sanchez-Martin, Manuel; van Ijzendoorn, Sven C. D.; Landolfi, Stefania; Hernandez-Losa, Javier; Schwartz Jr, Simo; Matias-Guiu, Xavier; Ramon y Cajal, Santiago; Martinez-Barriocanal, Agueda; Arango, Diego			Myosin Vb as a tumor suppressor gene in intestinal cancer	ONCOGENE			English	Article							MICROVILLUS INCLUSION DISEASE; APICAL PROTEIN LOCALIZATION; CELL POLARITY; COLORECTAL-CANCER; EPITHELIAL-CELLS; HUMAN-COLON; EXPRESSION; TRAFFICKING; MYO5B; PHOSPHORYLATION	Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.	[Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain; [Brotons, Bruno; Anguita, Estefania; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Inst Recerca Biomed Lleida IRBLleida, Grp Oncol Pathol, Lleida, Spain; [Sanchez-Martin, Manuel] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Serv Transgenesis, Nucleus, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Dept Med, Salamanca, Spain; [van Ijzendoorn, Sven C. D.] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Sci Cells & Syst, Sect Mol Cell Biol, Groningen, Netherlands; [Landolfi, Stefania; Hernandez-Losa, Javier; Ramon y Cajal, Santiago] Univ Autonoma Barcelona UAB, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Barcelona, Spain; [Landolfi, Stefania; Hernandez-Losa, Javier; Matias-Guiu, Xavier; Ramon y Cajal, Santiago] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Schwartz Jr, Simo] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Drug Delivery & Targeting, Barcelona, Spain; [Schwartz Jr, Simo] Vall dHebron Hosp, Clin Biochem Dept, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universitat de Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Groningen; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron	Arango, D (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain.; Arango, D (corresponding author), Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain.	darango@irblleida.cat	; Sanchez-Martin, Manuel/N-5327-2016	Tarragona, Jordi/0000-0002-1459-4087; Dopeso, Higinio/0000-0003-0060-1861; Sanchez-Martin, Manuel/0000-0001-8370-1336	World Cancer Research [AICR13-0245]; Instituto de Salud Carlos III [PI16/00540, PI19/00993, PI22/00773]; European Regional Development Fund [AC15/00066, AC19/00095, AC20/00022]; Spanish Association Against Cancer [AECC GCA15152966ARAN]; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	World Cancer Research; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund(European Commission); Spanish Association Against Cancer; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	This study was partially funded by grants of World Cancer Research (AICR13-0245), Instituto de Salud Carlos III (PI16/00540, PI19/00993, PI22/00773), the European Regional Development Fund (AC15/00066, AC19/00095, AC20/00022) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to DA. BB is supported by "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida.	Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bazzocco S, 2015, CLIN CANCER RES, V21, P3695, DOI 10.1158/1078-0432.CCR-14-2457; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Carton-Garcia F, 2015, SCI REP-UK, V5, DOI 10.1038/srep12312; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; D'Agostino L, 2019, CANCER RES, V79, P4099, DOI 10.1158/0008-5472.CAN-18-4075; Dhekne HS, 2014, J CELL SCI, V127, P1007, DOI 10.1242/jcs.137273; Dong WJ, 2012, DIGEST DIS SCI, V57, P1247, DOI 10.1007/s10620-011-1989-z; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gandalovicova A, 2016, ONCOTARGET, V7, P25022, DOI 10.18632/oncotarget.7214; Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983; Goldenring JR, 2013, NAT REV CANCER, V13, P813, DOI 10.1038/nrc3601; Groisman GM, 2000, HUM PATHOL, V31, P1404, DOI 10.1053/hupa.2000.19831; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Kranz A, 2010, GENESIS, V48, P512, DOI 10.1002/dvg.20641; Kravtsov D, 2014, AM J PHYSIOL-GASTR L, V307, pG992, DOI 10.1152/ajpgi.00180.2014; Kravtsov DV, 2016, AM J PHYSIOL-GASTR L, V311, pG142, DOI 10.1152/ajpgi.00041.2016; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Leng CS, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000531; Letellier E, 2017, BRIT J CANCER, V117, P1689, DOI 10.1038/bjc.2017.352; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mariadason JM, 2002, CANCER RES, V62, P4791; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller T, 2008, NAT GENET, V40, P1163, DOI 10.1038/ng.225; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nam KT, 2010, J CLIN INVEST, V120, P840, DOI 10.1172/JCI40728; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; PETERSON MD, 1992, J CELL SCI, V102, P581; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Roland JT, 2011, P NATL ACAD SCI USA, V108, P2789, DOI 10.1073/pnas.1010754108; ROWLATT C, 1970, J PATHOL, V100, pPR12; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Ruemmele FM, 2010, HUM MUTAT, V31, P544, DOI 10.1002/humu.21224; Sato T, 2007, NATURE, V448, P366, DOI 10.1038/nature05929; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schneeberger K, 2015, P NATL ACAD SCI USA, V112, P12408, DOI 10.1073/pnas.1516672112; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sobajima T, 2015, BIOL OPEN, V4, P86, DOI 10.1242/bio.20148532; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Thoeni Cornelia E, 2014, Traffic, V15, P22, DOI 10.1111/tra.12131; Weis VG, 2016, CELL MOL GASTROENTER, V2, P131, DOI 10.1016/j.jcmgh.2015.11.009; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	53	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5279	5288		10.1038/s41388-022-02508-2	http://dx.doi.org/10.1038/s41388-022-02508-2		NOV 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316444	Bronze			2022-12-26	WOS:000876857300001
J	Han, YN; Yang, QL; Huang, YP; Gao, PF; Jia, LF; Zheng, YF; Li, WR				Han, Yineng; Yang, Qiaolin; Huang, Yiping; Gao, Pengfei; Jia, Lingfei; Zheng, Yunfei; Li, Weiran			Compressive force regulates orthodontic tooth movement via activating the NLRP3 inflammasome	FASEB JOURNAL			English	Article						autophagy; cyclic GMP-AMP synthase; mechanical force; NLRP3 inflammasome	MACROPHAGE POLARIZATION; PERIODONTAL-LIGAMENT; CELL-PROLIFERATION; AUTOPHAGY; MECHANOTRANSDUCTION; OSTEOCLASTOGENESIS; CASPASES; PATHWAYS	Mechanical stress regulates various cellular functions like cell inflammation, immune responses, proliferation, and differentiation to maintain tissue homeostasis. However, the impact of mechanical signals on macrophages and the underlying mechanisms by which mechanical force regulates bone remodeling during orthodontic tooth movement remain unclear. NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been reported to promote osteoclastic differentiation to regulate alveolar bone resorption. But the relationship between the compressive force and NLRP3 inflammasome in macrophages remains unknown. In this study, immunohistochemical staining results showed elevated expression of NLRP3 and interleukin-1 beta, as well as an increased number of macrophages expressing NLRP3, on the compression side of the periodontal tissues, after force application for 7 days. Furthermore, the number of tartrate-resistant acid phosphatase-positive osteoclasts, and the mRNA and protein expression levels of osteoclast-related genes in the periodontal tissue decreased in the Nlrp3(-/-) mice compared to the WT mice group after orthodontic movement. In vitro mechanical force activates the NLRP3 inflammasome and inhibits autophagy. Intraperitoneal injection of the autophagy inhibitor 3-methyladenine in Nlrp3(-/-) mice promoted orthodontic tooth movement. This result indicates that the absence of NLRP3 inflammasome activation can be partially compensated for by autophagy inhibitors. Mechanistically, force-induced activation of the NLRP3 inflammasome in macrophages via the cGAS/P2X7R axis. In conclusion, compressive force regulates orthodontic tooth movement via activating the NLRP3 inflammasome.	[Han, Yineng; Yang, Qiaolin; Huang, Yiping; Zheng, Yunfei; Li, Weiran] Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China; [Han, Yineng] Zhejiang Univ, Stomatol Hosp, Zhejiang Prov Clin Res Ctr Oral Dis, Sch Stomatol,Sch Med,Key Lab Oral Biomed Res Zhej, Hangzhou, Peoples R China; [Han, Yineng; Yang, Qiaolin; Huang, Yiping; Jia, Lingfei; Zheng, Yunfei; Li, Weiran] Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China; [Gao, Pengfei] Peking Univ, Sch Life Sci, Key Lab Cell Proliferat & Differentiat, Minist Educ, Beijing, Peoples R China; [Gao, Pengfei] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Jia, Lingfei] Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing, Peoples R China; [Jia, Lingfei] Peking Univ, Cent Lab, Sch & Hosp Stomatol, Beijing, Peoples R China	Peking University; Zhejiang University; Peking University; Peking University; Peking University	Zheng, YF; Li, WR (corresponding author), Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.	yunfei_zheng@bjmu.edu.cn; weiranli@bjmu.edu.cn			National Natural Science Foundation of China [82071119, 82071142]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was financially supported by the National Natural Science Foundation of China (No. 82071119, 82071142).	Albalawi F, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00227; Allaeys I, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4365; Cadwell K, 2016, NAT REV IMMUNOL, V16, P661, DOI 10.1038/nri.2016.100; Chen LY, 2019, J PERIODONTOL, V90, P1170, DOI 10.1002/JPER.19-0049; Chen YH, 2015, GENE, V566, P13, DOI 10.1016/j.gene.2015.03.055; Chen YY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12973; Choi JW, 2011, J PERIODONTAL RES, V46, P513, DOI 10.1111/j.1600-0765.2011.01351.x; Danciu TE, 2004, J DENT RES, V83, P596, DOI 10.1177/154405910408300803; Taddei SRD, 2012, J BIOMECH, V45, P2729, DOI 10.1016/j.jbiomech.2012.09.006; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003; Gaidt MM, 2017, CELL, V171, P1110, DOI 10.1016/j.cell.2017.09.039; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720; Han YN, 2021, ORAL DIS, V27, P1268, DOI 10.1111/odi.13637; Hayakawa T, 2015, MOL MED REP, V12, P5879, DOI 10.3892/mmr.2015.4141; He D, 2015, J DENT RES, V94, P1286, DOI 10.1177/0022034515589714; He DQ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01607-9; Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x; Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016-015-8519-2; Iwawaki Y, 2015, J BIOSCI BIOENG, V120, P456, DOI 10.1016/j.jbiosc.2015.02.006; Jacox LA, 2022, AM J ORTHOD DENTOFAC, V161, P423, DOI 10.1016/j.ajodo.2020.09.034; Jiang N, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.666631; Jin SS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12912; Kameyama S, 2013, INT J MOL MED, V31, P292, DOI 10.3892/ijmm.2012.1220; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kim SM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02563; Lai MY, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00116; Li S, 2020, EXP CELL RES, V387, DOI 10.1016/j.yexcr.2019.111745; Li Y, 2021, AM J ORTHOD DENTOFAC, V159, P582, DOI 10.1016/j.ajodo.2020.01.027; Liu H, 2022, FASEB J, V36, DOI 10.1096/fj.202101589R; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Maruyama K, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232-019-0092-2; McCulloch CAG, 2000, PERIODONTOL 2000, V24, P56, DOI 10.1034/j.1600-0757.2000.2240104.x; Miller S, 2010, AUTOPHAGY, V6, P805, DOI 10.1126/science.1184429; Miroshnikova YA, 2018, NAT CELL BIOL, V20, P69, DOI 10.1038/s41556-017-0005-z; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Nakatsu S, 2014, J PERIODONTAL RES, V49, P314, DOI 10.1111/jre.12109; Spyropoulou A, 2015, BBA-MOL BASIS DIS, V1852, P1700, DOI 10.1016/j.bbadis.2015.05.010; Tan SD, 2007, BONE, V41, P745, DOI 10.1016/j.bone.2007.07.019; Viecilli RF, 2009, AM J ORTHOD DENTOFAC, V135, P694, DOI 10.1016/j.ajodo.2009.02.013; Yan Y, 2015, J DENT RES, V94, P1463, DOI 10.1177/0022034515595003; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Yum S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100225118; Zang Y, 2020, J DENT RES, V99, P1287, DOI 10.1177/0022034520933533; Zhang Y, 2014, J IMMUNOL, V192, P5296, DOI 10.4049/jimmunol.1400653; Zhao D, 2016, ONCOTARGET, V7, P68292, DOI 10.18632/oncotarget.11944	49	0	0	4	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2022	36	12							e22627	10.1096/fj.202200447RR	http://dx.doi.org/10.1096/fj.202200447RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5U2DE	36314562				2022-12-26	WOS:000876361900001
J	Zhao, BW; Huang, JQ; Lou, XT; Yao, K; Ye, M; Mou, QX; Wen, Z; Duan, QM; Zhang, H; Zhao, Y				Zhao, Bowen; Huang, Jingqiu; Lou, Xiaotong; Yao, Ke; Ye, Meng; Mou, Qianxue; Wen, Zheng; Duan, Qiming; Zhang, Hong; Zhao, Yin			Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated ANXA1 upregulation	FASEB JOURNAL			English	Article						ANXA1; BRB; endothelial junctions; vascular development; vascular integrity	GROWTH-FACTOR EXPRESSION; NEURODEGENERATIVE DISEASES; NEUROVASCULAR UNIT; BARRIER FUNCTION; CELL JUNCTIONS; VE-CADHERIN; PROTEIN; PERMEABILITY; INTEGRITY; ACTIN	Blood-retinal barrier (BRB) breakdown is responsible for multiple ocular diseases, such as diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive diseases. Increased vascular permeability contributes to vasogenic edema and tissue damage, with consequent adverse effects on vision. Herein, we found that endothelial CYP2J2 overexpression maintained BRB integrity after ischemia-reperfusion injury and consequently protected against retinal ganglion cell loss. Oxidative stress repressed endothelial ANXA1 expression in vivo and in vitro. CYP2J2 upregulated methyltransferase-like 3 (METTL3) expression and hence promoted ANXA1 translation via ANXA1 m(6)A modification in endothelium under oxidative stress. CYP2J2 maintained the distribution of endothelial tight junctions and adherens junctions in an ANXA1-dependent manner. Endothelial ANXA1 plays an indispensable role in vascular homeostasis and stabilization during development. Endothelial ANXA1 deletion disrupted retinal vascular perfusion as well as BRB integrity. CYP2J2 metabolites restored BRB integrity in the presence of ANXA1. Our findings identified the CYP2J2-METTL3-ANXA1 pathway as a potential therapeutic target for relieving BRB impairments.	[Zhao, Bowen; Lou, Xiaotong; Yao, Ke; Ye, Meng; Mou, Qianxue; Zhang, Hong; Zhao, Yin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Peoples R China; [Huang, Jingqiu] Wuhan Univ, Dept Ophthalmol, Zhongnan Hosp, Wuhan, Peoples R China; [Wen, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Div Cardiol, Wuhan, Peoples R China; [Duan, Qiming] Gladstone Inst, San Francisco, CA USA	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology; University of California System; University of California San Francisco; The J David Gladstone Institutes	Zhang, H; Zhao, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Peoples R China.	tjyksys@163.com; zhaoyin85@hust.edu.cn	wen, zheng/HII-3705-2022		National Natural Science Foundation of China [82070965]; Tongji Hospital (HUST) Foundation for Excellent Young Scientist [2020YQ18]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tongji Hospital (HUST) Foundation for Excellent Young Scientist	The current study was supported by funding from the National Natural Science Foundation of China (grant no. 31800868) and Tongji Hospital (HUST) Foundation for Excellent Young Scientist (grant no. 2020YQ18 to Dr. Yin Zhao), and the National Natural Science Foundation of China (grant no. 82070965 to Dr. Hong Zhang).	Aliwarga T, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060144; Amadio M, 2012, MOL VIS, V18, P2153; An YY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01500-4; Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4; Baker DJ, 2018, J CLIN INVEST, V128, P1208, DOI 10.1172/JCI95145; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016; Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3; Cai W, 2017, AGEING RES REV, V34, P77, DOI 10.1016/j.arr.2016.09.006; Cao J, 2021, REDOX BIOL, V45, DOI 10.1016/j.redox.2021.102031; Chen Q, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001374; Claesson-Welsh L, 2021, TRENDS MOL MED, V27, P314, DOI 10.1016/j.molmed.2020.11.006; Cristante E, 2013, P NATL ACAD SCI USA, V110, P832, DOI 10.1073/pnas.1209362110; Csortos C, 2007, AM J PHYSIOL-LUNG C, V293, pL843, DOI 10.1152/ajplung.00120.2007; Curtis TM, 2018, JOVE-J VIS EXP, DOI 10.3791/57944; Dalli J, 2008, BLOOD, V112, P2512, DOI 10.1182/blood-2008-02-140533; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; Delorme S, 2021, AM J CANCER RES, V11, P1600; Ding Y, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01891-w; Duplancic R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88101-1; Evangelista EA, 2018, DRUG METAB DISPOS, V46, P380, DOI 10.1124/dmd.117.078840; Geng HX, 2017, NEUROCHEM RES, V42, P2841, DOI 10.1007/s11064-017-2297-6; Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020; Giurdanella G, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11010051; Giurdanella G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207528; Grant ZL, 2020, J CLIN INVEST, V130, P4235, DOI 10.1172/JCI127668; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; Huang JQ, 2019, FASEB J, V33, P11194, DOI 10.1096/fj.201900756R; Hui QY, 2020, FREE RADICAL BIO MED, V146, P181, DOI 10.1016/j.freeradbiomed.2019.10.414; Iadecola C, 2017, NEURON, V96, P17, DOI 10.1016/j.neuron.2017.07.030; Ji LY, 2021, CELL MOL LIFE SCI, V78, P5977, DOI 10.1007/s00018-021-03893-9; Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279; Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003; Kida T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81482-3; Kom C, 2015, DEV CELL, V34, P5, DOI 10.1016/j.devcel.2015.06.004; Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534; Kulikauskas MR, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-021-04033-z; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Lenard A, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002126; Li XG, 2020, J CELL MOL MED, V24, P862, DOI 10.1111/jcmm.14796; Liu H, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.627110; Lou ZL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8836058; Luo Y, 2005, J CELL BIOL, V169, P29, DOI 10.1083/jcb.200411127; Minhas G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00444; Mukwaya A, 2021, EXP MOL MED, V53, P189, DOI 10.1038/s12276-021-00566-2; Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367; Musch MW, 2006, AM J PHYSIOL-GASTR L, V290, pG222, DOI 10.1152/ajpgi.00301.2005; Park JC, 2017, AGING CELL, V16, P149, DOI 10.1111/acel.12530; Pellicani R, 2020, MATRIX BIOL, V87, P11, DOI 10.1016/j.matbio.2019.08.002; Ries M, 2021, BRAIN, V144, P1526, DOI 10.1093/brain/awab050; Segarra M, 2018, SCIENCE, V361, DOI 10.1126/science.aao2861; Sharma M, 2009, PROSTAG OTH LIPID M, V89, P43, DOI 10.1016/j.prostaglandins.2009.04.004; Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064; Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200; Wettschureck N, 2019, PHYSIOL REV, V99, P1467, DOI 10.1152/physrev.00037.2018; Williams JM, 2007, AM J PHYSIOL-RENAL, V293, pF501, DOI 10.1152/ajprenal.00131.2007; Xiang J, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00864-9; Xu Q, 2017, FREE RADICAL BIO MED, V109, P84, DOI 10.1016/j.freeradbiomed.2017.03.004; Xu X, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02174-3; Yamazaki Y, 2016, STROKE, V47, P1068, DOI 10.1161/STROKEAHA.115.010835; Yang Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12718; Yi M, 2009, P NATL ACAD SCI USA, V106, P17886, DOI 10.1073/pnas.0901324106; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zhang CZ, 2020, ONCOGENE, V39, P4507, DOI 10.1038/s41388-020-1303-7; Zhao QS, 2018, J MOL CELL CARDIOL, V123, P118, DOI 10.1016/j.yjmcc.2018.08.027; Zheng B, 2017, MOL THER, V25, P1279, DOI 10.1016/j.ymthe.2017.03.031; Zhuang MR, 2019, NUCLEIC ACIDS RES, V47, P4765, DOI 10.1093/nar/gkz157	68	0	0	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22619	10.1096/fj.202201061RR	http://dx.doi.org/10.1096/fj.202201061RR			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5M0IN	36269280				2022-12-26	WOS:000870790600001
J	Mannelli, M; Gamberi, T; Garella, R; Magherini, F; Squecco, R; Fiaschi, T				Mannelli, Michele; Gamberi, Tania; Garella, Rachele; Magherini, Francesca; Squecco, Roberta; Fiaschi, Tania			Pyruvate prevents the onset of the cachectic features and metabolic alterations in myotubes downregulating STAT3 signaling	FASEB JOURNAL			English	Article						cancer cachexia; metabolism; pyruvate	UBIQUITIN-PROTEASOME SYSTEM; SKELETAL-MUSCLE; MITOCHONDRIAL; CACHEXIA; INHIBITION; TRANSPORT; PATHWAY; MODEL; IL-6	Cachexia is a systemic disease associated with several pathologies, including cancer, that leads to excessive weight loss due to enhanced protein degradation. Previously, we showed that cachectic features in myotubes are provoked by a metabolic shift toward lactic fermentation. Our previous results led us to hyphotesise that increasing pyruvate concentration could impede the metabolic modifications responsible for induction of cachexia in myotubes. Here, we demonstrated that the addition of sodium pyruvate in conditioned media from CT26 colon cancer cells (CM CT26) prevents the onset of either phenotypic and metabolic cachectic features. Myotubes treated with CM CT26 containing sodium pyruvate show a phenotype similar to the healthy counterpart and display lactate production, oxygen consumption, and pyruvate dehydrogenase activity as control myotubes. The use of the Mitochondrial Pyruvate Carrier inhibitor UK5099, highlights the importance of mitochondrial pyruvate amount in the prevention of cachexia. Indeed, UK5099-treated myotubes show cachectic features as those observed in myotubes treated with CM CT26. Finally, we found that sodium pyruvate is able to decrease STAT3 phosphorylation level, a signaling pathway involved in the induction of cachexia in myotubes. Collectively, our results show that cachexia in myotubes could be prevented by the utilization of sodium pyruvate which impedes the metabolic modifications responsible for the acquisition of the cachectic features.	[Mannelli, Michele; Gamberi, Tania; Magherini, Francesca; Fiaschi, Tania] Univ Firenze, Dipartimento Sci Biomed Sperimentali & Clin Mario, Viale Morgagni 50, I-50134 Florence, Italy; [Garella, Rachele; Squecco, Roberta] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy	University of Florence; University of Florence	Fiaschi, T (corresponding author), Univ Firenze, Dipartimento Sci Biomed Sperimentali & Clin Mario, Viale Morgagni 50, I-50134 Florence, Italy.	tania.fiaschi@unifi.it			Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)	Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR), Grant/Award Number: RICATEN	Anwar S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568; Argiles JM, 1996, TRENDS PHARMACOL SCI, V17, P223, DOI 10.1016/0165-6147(96)10021-3; Bernacchioni C, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11040713; Bilodeau PA, 2016, AM J PHYSIOL-CELL PH, V311, pC392, DOI 10.1152/ajpcell.00125.2016; Bodine SC, 2014, AM J PHYSIOL-ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099; Fontes-Oliveira CC, 2013, BBA-GEN SUBJECTS, V1830, P2770, DOI 10.1016/j.bbagen.2012.11.009; Der-Torossian H, 2013, J CACHEXIA SARCOPENI, V4, P145, DOI 10.1007/s13539-012-0101-7; Du JH, 2013, J BIOL CHEM, V288, P36129, DOI 10.1074/jbc.M113.507285; Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Fermoselle C, 2013, EXP PHYSIOL, V98, P1349, DOI 10.1113/expphysiol.2013.072496; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; Hildyard JCW, 2005, BBA-BIOENERGETICS, V1707, P221, DOI 10.1016/j.bbabio.2004.12.005; Hu WJ, 2019, BBA-MOL CELL BIOL L, V1864, P1091, DOI 10.1016/j.bbalip.2019.04.006; Ma JF, 2017, EMBO MOL MED, V9, P622, DOI 10.15252/emmm.201607052; Mannelli M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060698; Martella D, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103077; Miller A, 2017, ONCOGENE, V36, P3059, DOI 10.1038/onc.2016.437; Nunes AM, 2017, HUM MOL GENET, V26, P2018, DOI 10.1093/hmg/ddx083; PAPA S, 1971, FEBS LETT, V12, P285, DOI 10.1016/0014-5793(71)80200-4; Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217; Penna F, 2019, J MOL BIOL, V431, P2674, DOI 10.1016/j.jmb.2019.05.032; Pin F, 2019, FASEB J, V33, P7778, DOI 10.1096/fj.201802799R; Pin F, 2019, J CACHEXIA SARCOPENI, V10, P140, DOI 10.1002/jcsm.12360; Porporato PE, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.3; Silva KAS, 2015, J BIOL CHEM, V290, P11177, DOI 10.1074/jbc.M115.641514; Sgrignani J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33048-z; Sharma A, 2019, ELIFE, V8, DOI 10.7554/eLife.45873; Shukla SK, 2020, CANCER LETT, V484, P29, DOI 10.1016/j.canlet.2020.04.017; Tzika AA, 2013, INT J ONCOL, V43, P886, DOI 10.3892/ijo.2013.1998; Vacanti NM, 2014, MOL CELL, V56, P425, DOI 10.1016/j.molcel.2014.09.024; Wada E, 2017, SKELET MUSCLE, V7, DOI 10.1186/s13395-017-0140-z; Ying L, 2022, AM J PHYSIOL-CELL PH, V322, pC814, DOI 10.1152/ajpcell.00463.2021; Zimmers TA, 2016, SEMIN CELL DEV BIOL, V54, P28, DOI 10.1016/j.semcdb.2016.02.009	36	0	0	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22598	10.1096/fj.202200848R	http://dx.doi.org/10.1096/fj.202200848R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5R9PP	36305891				2022-12-26	WOS:000874835600001
J	Wang, LJ; Wang, C; Sarwar, MS; Chou, PC; Wang, YJ; Su, XY; Kong, ANT				Wang, Lujing; Wang, Chao; Sarwar, Md Shahid; Chou, Pochung; Wang, Yujue; Su, Xiaoyang; Kong, Ah-Ng Tony			PTEN-knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid	FASEB JOURNAL			English	Article						chemoprevention; epigenetic; metabolomics; prostate cancer; PTEN; ursolic acid	GENE; METHYLATION; GLYCOLYSIS; PREVENTION; APOPTOSIS; DELETION; ALIGNER; PACKAGE; PATHWAY; GROWTH	PTEN (phosphatase and tensin homolog deleted on chromosome 10) is one of the most frequently mutated/deleted tumor suppressor genes in many human cancers. Ursolic acid (UA) is a natural triterpenoid possessing antioxidant, anti-inflammatory, and anticancer effects. However, how PTEN impacts metabolic rewiring and how UA modifies PTEN-driven metabolic and epigenetic reprogramming in prostate cancer (PCa) remains unknown. In the current study, we found that UA protects against PTEN knockout (KO)-induced tumorigenesis at different stages of PCa. Epigenomic CpG methyl-seq revealed UA attenuated PTEN KO-induced differentially methylated regions (DMRs) profiles. Transcriptomic RNA-seq showed UA abrogated PTEN KO-induced differentially expressed genes (DEGs) of PCa-related oncogenes' Has3, Cfh, and Msx1 overexpression, indicating UA plays a crucial role in PTEN KO-mediated gene regulation and its potential consequences on cancer interception. Association analysis of DEGs and DMRs identified that the mRNA expression of tumor suppressor gene BDH2, and oncogenes Ephas, Isg15, and Nos2 were correlated with the promoter CpG methylation status in the early-stage comparison groups indicating UA could regulate the oncogenes or tumor suppressor genes by modulating their promoter methylation at an early stage of prostate tumorigenesis. The metabolomic study showed UA attenuated PTEN KO-regulated cancer-associated metabolisms like purine metabolism/metabolites correlating with RNAseq findings, glycolysis/gluconeogenesis metabolism, as well as epigenetic-related metabolites pyruvate and lactate indicating UA plays a critical role in PTEN KO-mediated metabolic and epigenetic reprogramming and its consequences on cancer development. In this context, UA impacts metabolic rewiring causing epigenetic and transcriptomic reprogramming potentially contributing to the overall protection against prostate-specific PTEN KO-mediated PCa.	[Wang, Lujing; Sarwar, Md Shahid; Chou, Pochung; Kong, Ah-Ng Tony] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut Sci, Piscataway, NJ USA; [Wang, Lujing; Wang, Chao; Chou, Pochung; Kong, Ah-Ng Tony] Rutgers State Univ, Ernest Mario Sch Pharm, Grad Program Pharmaceut Sci, Piscataway, NJ USA; [Wang, Yujue; Su, Xiaoyang] Rutgers Canc Inst New Jersey, Metabol Shared Resource, New Brunswick, NJ USA; [Wang, Yujue; Su, Xiaoyang] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Ctr Phytochem Epigenome Studies, Dept Pharmaceut, Piscataway, NJ 08854 USA.	kongt@pharmacy.rutgers.edu	Wang, Yujue/HHN-4296-2022		HHS | NIH | National Center for Complementary and Integrative Health (NCCIH) [R01 AT009152]; HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) [P30 ES005022]	HHS | NIH | National Center for Complementary and Integrative Health (NCCIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHS | NIH | National Institute of Environmental Health Sciences (NIEHS)	HHS | NIH | National Center for Complementary and Integrative Health (NCCIH), Grant/Award Number: R01 AT009152; HHS | NIH | National Institute of Environmental Health Sciences (NIEHS), Grant/Award Number: P30 ES005022	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Alvarez-Cubero MJ, 2017, MOL DIAGN THER, V21, P167, DOI 10.1007/s40291-016-0248-6; Amankwah EK, 2012, CARCINOGENESIS, V33, P1259, DOI 10.1093/carcin/bgs150; Becker LM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107701; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524; Chen PJ, 2014, ONCOL LETT, V8, P41, DOI 10.3892/ol.2014.2093; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Conteduca V, 2021, TRANSL ANDROL UROL, V10, P3104, DOI 10.21037/tau-20-1339; Cooke J, 2012, INFLAMM BOWEL DIS, V18, P2128, DOI 10.1002/ibd.22942; Coronel-Hernandez J, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.676562; Cyr AR, 2011, ANTIOXID REDOX SIGN, V15, P551, DOI 10.1089/ars.2010.3492; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; De Vitto H, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102603; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Gaspar JM, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1909-0; Guo Y, 2017, BIOCHEM PHARMACOL, V135, P22, DOI 10.1016/j.bcp.2017.02.021; Hirsh S., 2014, FASEB J, V28, DOI 10.1096/ fasebj.28.1_supplement. 1044.6 1044.6; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Ikeda Y, 2008, MOL NUTR FOOD RES, V52, P26, DOI 10.1002/mnfr.200700389; Islam RA, 2017, CURR CANCER DRUG TAR, V17, P707, DOI 10.2174/1568009617666170330150458; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Janke R, 2015, ANNU REV CELL DEV BI, V31, P473, DOI 10.1146/annurev-cellbio-100814-125544; Kariri YA, 2021, BREAST CANCER RES TR, V185, P293, DOI 10.1007/s10549-020-05955-1; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim H, 2016, J NUTR BIOCHEM, V33, P54, DOI 10.1016/j.jnutbio.2015.09.014; Kozuka T, 2011, J IMMUNOL, V187, P5974, DOI 10.4049/jimmunol.1100550; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Latham T, 2012, NUCLEIC ACIDS RES, V40, P4794, DOI 10.1093/nar/gks066; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li SY, 2022, MOL CARCINOGEN, V61, P111, DOI 10.1002/mc.23365; Liang H, 2019, J CANCER, V10, P3735, DOI 10.7150/jca.32022; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Locato V, 2018, J EXP BOT, V69, P3373, DOI 10.1093/jxb/ery168; Lodi A, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0024-z; Martin M, 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, 10.10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Maxwell PJ, 2013, EUR UROL, V64, P177, DOI 10.1016/j.eururo.2012.08.032; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Neagu M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00348; Parker WB, 2009, CHEM REV, V109, P2880, DOI 10.1021/cr900028p; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Ramirez CN, 2018, AAPS J, V20, DOI 10.1208/s12248-017-0177-2; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Seo DY, 2018, KOREAN J PHYSIOL PHA, V22, P235, DOI 10.4196/kjpp.2018.22.3.235; Sfanos KS, 2012, HISTOPATHOLOGY, V60, P199, DOI 10.1111/j.1365-2559.2011.04033.x; Shanmugam MK, 2013, BIOCHEM PHARMACOL, V85, P1579, DOI 10.1016/j.bcp.2013.03.006; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Staal J, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090122; Su XY, 2016, CURR OPIN CHEM BIOL, V30, P52, DOI 10.1016/j.cbpa.2015.10.030; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thakur C, 2019, SEMIN CANCER BIOL, V57, P52, DOI 10.1016/j.semcancer.2019.06.006; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Valkenburg KC, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/895238; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Villa E, 2019, CANCERS, V11, DOI 10.3390/cancers11050688; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang C, 2020, FASEB J, V34, P1304, DOI 10.1096/fj.201901205RR; Wang L., 2022, MOL NUTR FOOD RES, V66; Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612; Wang LJ, 2022, AAPS J, V24, DOI 10.1208/s12248-022-00679-0; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160, DOI 10.1289/ehp.114-a160; Willkomm L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176609; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Wu RY, 2022, FREE RADICAL BIO MED, V179, P328, DOI 10.1016/j.freeradbiomed.2020.12.007; Wu RY, 2020, MOL CARCINOGEN, V59, P227, DOI 10.1002/mc.23146; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145	76	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2022	36	11							e22626	10.1096/fj.202201195R	http://dx.doi.org/10.1096/fj.202201195R			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	5R6GT	36305462				2022-12-26	WOS:000874607500001
J	Yan, C; Yang, HJ; Su, P; Li, X; Li, ZB; Wang, DH; Zang, YF; Wang, TS; Liu, ZP; Bao, ZC; Dong, SX; Zhuang, T; Zhu, J; Ding, YL				Yan, Cheng; Yang, Huijie; Su, Peng; Li, Xin; Li, Zhongbo; Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Dong, Shuxiao; Zhuang, Ting; Zhu, Jian; Ding, Yinlu			OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer	ONCOGENE			English	Article							ORGAN SIZE CONTROL; CELL-PROLIFERATION; PATHWAY; INVASION	Gastric cancer is one of the most lethal human malignancies in the world. Although great efforts are put in developing novel therapeutic targets, the effective targeting drugs are still limited. Recent studies reveal the abnormality of Hippo/YAP axis play critical role in the oncogenic process of gastric cancer. It is of great importance to demonstrate the regulation of Hippo signaling activity and YAP protein turnover in gastric cancer. Besides, the phosphorylation cascade on YAP function, which has been thoroughly investigated, the ubiquitination of YAP is also important in Hippo signaling status. Here, We utilized the DUB (Deubiquitinase) siRNA library to identify critical DUB for Hippo signaling. We discovered OTUB1 as a critical factor to facilitate gastric cancer cell stemness and progression, which deubiquitinated and stabilized YAP protein. The clinical data analysis implicated OTUB1 was higher expressed in gastric cancer, which correlated with YAP activity and poor survival. OUTB1 interacted with YAP protein via its OTU domain (Ovarian tumor domain) and deubiquitinated YAP at several lysine sites (K90, K280, K343, K494 and K497), which subsequently inhibited YAP degradation. Our study revealed a novel deubiquitinase of Hippo/YAP axis and one possible therapeutic target for YAP-driven gastric cancer.	[Yan, Cheng] Xinxiang Univ, Sch Med, Key Lab Nanocarbon Modified Film Technol Henan Pr, Diagnost Lab Anim Dis, Xinxiang 453003, Henan, Peoples R China; [Yang, Huijie; Li, Xin; Li, Zhongbo; Zhuang, Ting] Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan 250033, Peoples R China; [Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Zhu, Jian; Ding, Yinlu] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China; [Dong, Shuxiao] Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China; [Zhu, Jian] Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China; [Zhu, Jian] Shandong Acad Med Sci, Jinan 250013, Peoples R China	Xinxiang University; Xinxiang Medical University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Zhuang, T (corresponding author), Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China.; Zhu, J; Ding, YL (corresponding author), Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China.; Dong, SX (corresponding author), Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China.; Zhu, J (corresponding author), Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China.; Zhu, J (corresponding author), Shandong Acad Med Sci, Jinan 250013, Peoples R China.	dongsx01@163.com; 77090993@qq.com; jian.zhu@email.sdu.edu.cn; dingyinlu@126.com			National Science Foundation of China [82172999, 82273013]; Program for Science & Technology Innovation Talents in Universities of Henan Province [21HASTIT049]; Henan Provincial National Natural Science Foundation of Excellent Young Scientist [222300420065]; Taishan Scholar Program of Shandong Province [tsqn202103175]; Shandong Provincial National Natural Science Foundation [ZR2016HQ44, ZR2021MH017]; Key Research Program of Education Department of Henan Province [22A310005]; National Science Foundation for Young Scholars of China [32200632]; Program for Science & Technology Innovation in Shandong Society of Geriatrics [LKJGG2021z002]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation Talents in Universities of Henan Province; Henan Provincial National Natural Science Foundation of Excellent Young Scientist; Taishan Scholar Program of Shandong Province; Shandong Provincial National Natural Science Foundation; Key Research Program of Education Department of Henan Province; National Science Foundation for Young Scholars of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation in Shandong Society of Geriatrics	The project was supported by the National Science Foundation of China (No. 82172999, TZ; 82273013, YD), the Program for Science & Technology Innovation Talents in Universities of Henan Province (Grant No. 21HASTIT049 to TZ), the Henan Provincial National Natural Science Foundation of Excellent Young Scientist (222300420065 to TZ), the Taishan Scholar Program of Shandong Province (tsqn202103175 to JZ), Shandong Provincial National Natural Science Foundation (ZR2016HQ44 to YD; ZR2021MH017 for JZ), the Key Research Program of Education Department of Henan Province (22A310005 to JZ), the National Science Foundation for Young Scholars of China (32200632 to Cheng Yan) and the Program for Science & Technology Innovation in Shandong Society of Geriatrics (LKJGG2021z002 to YD).	Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; Boopathy GTK, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00049; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cenitagoya GF, 1998, DIGEST SURG, V15, P317, DOI 10.1159/000018645; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Garattini SK, 2017, WORLD J GASTRO ONCOL, V9, P194, DOI 10.4251/wjgo.v9.i5.194; Gerson JN, 2017, EXPERT OPIN INV DRUG, V26, P531, DOI 10.1080/13543784.2017.1315406; He MJ, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0013-6; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; Kim J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00314; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Padmanabhan R, 2020, CANCERS, V12, DOI 10.3390/cancers12030636; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rodriquenz MG, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051427; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Weng WW, 2016, AM J TRANSL RES, V8, P2234; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou XF, 2019, NAT IMMUNOL, V20, P879, DOI 10.1038/s41590-019-0405-2; Zhu D, 2021, CELL DEATH DIFFER, V28, P1773, DOI 10.1038/s41418-020-00700-z; Zhu H, 2020, CANCER RES, V80, P2204, DOI 10.1158/0008-5472.CAN-19-2388	34	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5186	5198		10.1038/s41388-022-02507-3	http://dx.doi.org/10.1038/s41388-022-02507-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271031	Green Published, hybrid			2022-12-26	WOS:000870984500002
J	Watanabe, K; Kimura, S; Seki, M; Isobe, T; Kubota, Y; Sekiguchi, M; Sato-Otsubo, A; Hiwatari, M; Kato, M; Oka, A; Koh, K; Sato, Y; Tanaka, H; Miyano, S; Kawai, T; Hata, K; Ueno, H; Nannya, Y; Suzuki, H; Yoshida, K; Fujii, Y; Nagae, G; Aburatani, H; Ogawa, S; Takita, J				Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Koh, Katsuyoshi; Sato, Yusuke; Tanaka, Hiroko; Miyano, Satoru; Kawai, Tomoko; Hata, Kenichiro; Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Nagae, Genta; Aburatani, Hiroyuki; Ogawa, Seishi; Takita, Junko			Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism	ONCOGENE			English	Article							ARGININE DEPRIVATION; SERINE BIOSYNTHESIS; GENE-EXPRESSION; SULFASALAZINE; CLASSIFICATION; PROLIFERATION; INHIBITOR; LYMPHOMA; SUPPORTS; GLYCINE	Neuroblastomas require novel therapies that are based on the exploitation of their biological mechanism. To address this need, we analyzed the DNA methylation and expression datasets of neuroblastomas, extracted a candidate gene characterizing the aggressive features, and conducted functional studies. Based on the DNA methylation data, we identified a subgroup of neuroblastoma cases with 11q loss of heterozygosity with extremely poor prognosis. PHGDH, a serine metabolism-related gene, was extracted as a candidate with strong expression and characteristic methylation in this subgroup as well as in cases with MYCN amplification. PHGDH inhibition suppressed neuroblastoma cell proliferation in vitro and in vivo, indicating that the inhibition of serine metabolism by PHGDH inhibitors is a therapeutic alternative for neuroblastoma. Inhibiting the arginine metabolism, which is closely related to serine metabolism using arginine deiminase, had a combination effect both in vitro and in vivo, especially on extracellular arginine-dependent neuroblastoma cells with ASS1 deficiency. Expression and metabolome analyses of post-dose cells confirmed the synergistic effects of treatments targeting serine and arginine indicated that xCT inhibitors that inhibit cystine uptake could be candidates for further combinatorial treatment. Our results highlight the rational therapeutic strategy of targeting serine/arginine metabolism for intractable neuroblastoma.	[Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Takita, Junko] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Kimura, Shunsuke] Hiroshima Univ, Dept Pediat, Grad Sch Biomed Sci, Hiroshima, Japan; [Hiwatari, Mitsuteru] Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Koh, Katsuyoshi] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan; [Sato, Yusuke] Univ Tokyo, Dept Urol, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Dept Integrated Analyt, Tokyo, Japan; [Kawai, Tomoko; Hata, Kenichiro] Natl Res Inst Child Hlth & Dev, Dept Maternal Fetal Biol, Tokyo, Japan; [Hata, Kenichiro] Gunma Univ, Dept Mol & Med Genet, Grad Sch Med, Maebashi, Gumma, Japan; [Ueno, Hiroo; Takita, Junko] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Suzuki, Hiromichi] Natl Canc Ctr, Div Brain Tumor Translat Res, Tokyo, Japan; [Nagae, Genta; Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Div, Tokyo, Japan; [Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Dept Pathol & Tumor Biol, Kyoto, Japan	University of Tokyo; Hiroshima University; Teikyo University; Saitama Children's Medical Center; University of Tokyo; Tokyo Medical & Dental University (TMDU); National Center for Child Health & Development - Japan; Gunma University; Kyoto University; Kyoto University; National Cancer Center - Japan; University of Tokyo; Kyoto University	Takita, J (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan.; Takita, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan.	jtakita@kuhp.kyoto-u.ac.jp		Seki, Masafumi/0000-0003-4671-7026; Isobe, Tomoya/0000-0002-3487-3307; Kubota, Yasuo/0000-0002-7909-5422; Sekiguchi, Masahiro/0000-0002-7941-9319	JSPS KAKENHI [JP19J11112, JP21K20795, JP22K15521, JP17H04224, JP18K19467, JP20H00528, JP21K19405, 15H05909, 19H05656, JP19cm0106509h9904]; Japan Agency for Medical Research and Development (AMED) [JP19cm0106509h9904, JP22ama221505h0001, JP19ck0106468h0001]; Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	This work was supported by JSPS KAKENHI Grant Numbers JP19J11112, JP21K20795, and JP22K15521 to KW; JP17H04224, JP18K19467, JP20H00528, and JP21K19405 to JT; 15H05909 and 19H05656 to SO and YN; Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. JP19cm0106509h9904), Project for Promotion of Cancer Research and Therapeutic Evolution (P-PROMOTE; grant no. JP22ama221505h0001), Practical Research for Innovative Cancer Control (grant no. JP19ck0106468h0001) from Japan Agency for Medical Research and Development (AMED), and Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan, and Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics to KW.	Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Arlt B, 2021, INT J CANCER, V148, P1219, DOI 10.1002/ijc.33423; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dillon BJ, 2004, CANCER-AM CANCER SOC, V100, P826, DOI 10.1002/cncr.20057; Ensor CM, 2002, CANCER RES, V62, P5443; Feun L, 2008, CURR PHARM DESIGN, V14, P1049, DOI 10.2174/138161208784246199; Fultang L, 2019, CANCER RES, V79, P611, DOI 10.1158/0008-5472.CAN-18-2139; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Haryu S, 2018, J NEURO-ONCOL, V136, P23, DOI 10.1007/s11060-017-2621-7; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Hishiki T, 2018, INT J CLIN ONCOL, V23, P965, DOI 10.1007/s10147-018-1281-8; Irwin MS, 2021, J CLIN ONCOL, V39, P3229, DOI 10.1200/JCO.21.00278; Ji JX, 2020, CLIN CANCER RES, V26, P4402, DOI 10.1158/1078-0432.CCR-19-1905; Ji XM, 2018, ONCOGENE, V37, P5007, DOI 10.1038/s41388-018-0307-z; Kremer JC, 2017, CELL REP, V18, P991, DOI 10.1016/j.celrep.2016.12.077; Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/NMETH.1828, 10.1038/nmeth.1828]; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113; Nakagawara A, 2018, JPN J CLIN ONCOL, V48, P214, DOI 10.1093/jjco/hyx176; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pizzo PA, 2015, PRINCIPLES PRACTICE; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sekiguchi M, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0125-y; Shitara K, 2017, GASTRIC CANCER, V20, P1004, DOI 10.1007/s10120-017-0720-y; Toya Y, 2007, J CHROMATOGR A, V1159, P134, DOI 10.1016/j.chroma.2007.04.011; Vandekeere S, 2018, CELL METAB, V28, P573, DOI 10.1016/j.cmet.2018.06.009; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xia YF, 2019, CANCER RES, V79, P3837, DOI 10.1158/0008-5472.CAN-18-3541; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028	48	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					4994	5007		10.1038/s41388-022-02489-2	http://dx.doi.org/10.1038/s41388-022-02489-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36319669	Green Published, hybrid			2022-12-26	WOS:000877420400001
